EXPRESSION ELEMENT

Abstract: The present invention is concerned with the use of the sequence CGGCAGGGTCTC, or a variant, homologue or fragment thereof, as a control element for activating transcription of a nucleotide sequence or nucleotide sequences from a promoter. The invention accordingly provides nucleic acid constructs in which at least one heterologous copy of the element is operatively liniked upstream or downstream of a promoter which is itself operatively linked to a nucleotide sequence.

Description: F.ypression Element The present invention relates to an expression element suitable for the increasing the levels of expression of polypeptides in cells or organisms. In particular, the invention relates to an expression element having the sequence CGGCAGGGTCTC. Xylan, a heterogeneous polysaccharide commonly found in plant cell walls, is one of the most common polysaccharides in nature. Xylanase is one of the major enzymes involved in the breakdown of xylan, catalysing the digestion of xylan into oligoxylose subunits. Xylanase enzymes and corresponding genes have been isolated from a very large number of different organisms. Examples include xylanases A and B from Penicillium, xylanase A from Thermotoga maritima and Bacillus subtilis, xylanases B and D from Ruminococcus flavefaciens, and many others. It is generally established that it is desirable to direct expression of a heterologous nucleotide sequence in an organism, such as a filamentous fungus (e.g. Aspergillus niger), or yeast. The resultant protein or enzyme may then be used in industry. Alternatively, the resultant protein or enzyme may be useful for the organism itself. For example, it may be desirable to produce fungal protein products with an optimised amino acid composition and so increase the nutritive value thereof. For example, the fungus may be made more useful as a feed. In the alternative, it may be desirable to isolate the resultant protein or enzyme and then use the protein or enzyme to prepare, for example, food compositions. In this regard, the resultant protein or enzyme can be a component of the food composition or it can be used to prepare food compositions, including altering the characteristics or appearance of food compositions. It may even be desirable to use the organism, such as a filamentous fungus or a yeast, to express heterologous genes, such as for the same purposes. Filamentous fungi in particular are attractive hosts for the large-scale production of proteins in industry. They have the capacity to secrete a large amount of heterologous and/or homologous protein into their growth medium, they have been extensively studied and are well known, and moreover they are considered safe for use in the preparation of products useful in the food, feed and beverage industries. They are known for their ability to secrete several hydrolytic enzymes, amongst which number the xylanases. A number of different xylanases are known and have been characterised and/or cloned (for example, see Ito, et al, (1992) Biosci. Biotech. Biochem. 5.6:906-912), including xylanases from ,4. awamori, A. kawachii and xylanases A, B and C from Aspergillus tubingensis. Of the latter, xylanase B is known to be more weakly expressed (see WO 94/14965). In general, xylanases belong to one of two families of glycosyl hydrolases, family H and family F. There is little homology between the two families, but within each family there is some sequence identity. For example, xylanases A and B of A. tubingensis belong to family H and share approximately 45% sequence identity at the amino acid level. For heterologous expression in filamentous fungi, as well as the vast majority of other organisms, it is desirable to use a strong promoter to direct expression of the gene in question. Usually it is assumed that highly expressed genes contain a strong promoter and consequently promoters derived from highly expressed genes are frequently used for this purpose. Examples of expression systems for use in filamentous fungi include systems employing the glucoamylase promoter (US 5,198,345) and the A. awamori xylanase A (xlnA) promoter (Gouka, et al, (1996) Appl. Microbiol. Biotechnol. 46, 28-35). De Graaff et al. , in xylans and xylanases , J. Visser et al. (eds.), 1992:235-246, Elsevier, and De Graaff et al. , (1994) Molecular Microbiology 12:479-490, have identified a 158bp upstream regulatory region of the A. tubingensis xlnA gene which is responsible for activation of transcription from the xlnA promoter. This region contains inter alia a sequence which comprises three repeats of the element GTCCATTTAGCCA. De Graaff et al. showed that the entire 158bp region was capable of activating an A. niger glucose oxidase gene igoxQ core promoter. It was not, however, determined whether the element GTCCATTTAGCCA was itself responsible for the activity of the upstream region or the activating effect. According to a first aspect of the present invention there is provided the use of a nucleic acid element having the sequence CGGCAGGGTCTC to modulate transcription of a nucleotide sequence from a promoter. Preferably, the promoter is a core promoter. The present invention is concerned with the use of the sequence CGGCAGGGTCTC as a control element for modulating transcription of a nucleotide sequence or nucleotide sequences from a promoter. The invention accordingly provides nucleic acid constructs in which at least one heterologous copy of the element is operatively linked to a promoter which is itself operatively linked to a nucleotide sequence, vectors containing such nucleic acid constructs and host cells transformed with such vectors and/or expressing DNA constructs according to the invention. Moreover, the invention concerns the use of multiple copies of the activating element operatively linked to the promoter, in order to provide further activation of transcription. In a further aspect, the invention concerns a sequence variant of the A. tubingensis xlnB gene which possesses enhanced expression characteristics as a result of the presence of three, rather than two, copies of the element of the invention upstream of the TATA box, as well as the use of this variant in nucleic acid constructs as above. The element according to the invention is preferably placed upstream of a promoter which is operatively linked to a nucleotide sequence. The nucleotide sequence is preferably a heterologous nucleotide sequence. Where a promoter already contains, in its upstream sequences, one or two copies of the regulatory element of the invention, an exogenous copy or copies is added in accordance with the invention in order to further activate transcription from this promoter. The optimum number of elements is three. The presence of more than three elements is detrimental to transcriptional activation. The use of four or more elements is applicable where a lower, but still significant, level of transcription is desired. Thus, the invention may be applied to the modulation (downregulation as well as the upregulation) of transcription from a promoter. Preferably, the element of the invention is used to upregulate transcription from the promoter, such that the rate of transcription is increased. Where more than one copy of the element of the invention is present, the elements may overlap. Thus, for example, the initial nucleotide of one element may also be the terminal nucleotide of another element. Preferably, the elements overlap by 1, 2 or 3 nucleotides. Preferably, the sequence of an overlapping element is GGCAGGGTCTCGGC AGGGTCTC. Preferably, the activated promoter linked to the nucleotide sequence according to the invention is incorporated into a nucleic acid construct, which may be a plasmid vector or the like. Advantageously, a vector according to the invention is an expression vector. As stated above, three copies of the element provide the strongest transcriptional activation, being highly preferred to two elements. The addition of further elements, above three, leads to a progressive reduction in the activation level, as described in further detail in the accompanying examples. Expression vectors according to the invention are useful for transforming cells. The invention accordingly provides cells transformed with vectors according to the invention, for the expression of polypeptides encoded by the heterologous nucleotide sequence. The transformed cells may be cultured cells, for example in tissue culture or organ culture, but also cells which form all or part of a discrete living organism. The invention accordingly provides a transgenic non-human organism which has been transformed with a nucleic acid construct according to the invention. Such organisms may be unicellular or multicellular. Especially preferred are yeasts and filamentous fungi, especially Aspergillus. In a second aspect of the present invention, there is provided a sequence variant of the A. tubingensis xlnB promoter, characterised in that it possesses at least three copies of the element CGGCAGGGTCTC. The xylanase B gene is weakly expressed (WO 94/14965) and on account of its being seen as possessing a weak promoter has never been suggested to be a suitable basis for heterologous expression systems. A surprisingly effective sequence variant of the xylanase B promoter, which is particularly strong and suitable for the expression of heterologous nucleotide sequences, has now been isolated and compared to the promoter disclosed in WO 94/14965. The new sequence variant differs from the promoter of WO 94/14965 in the presence of three copies of the element CGGCAGGGTCTC rather than just two. The presence of the extra element is thought to be responsible for the observed increase in transcriptional activation. The preferred sequence of the variant according to the invention is that of the xlnB promoter as hereinbefore defined shown in SEQ. ID. No. 1, or a variant, homologue or fragment thereof, provided that the variant, homologue or fragment retains at least three copies of the element according to the invention. The promoter in SEQ. ID. No. 1 is located upstream of the translation start site, and in a preferred embodiment the promoter possesses the sequence as shown between positions 1 and 720 of SEQ. ID. No. 1. Advantageously, the promoter possesses a shorter sequence, preferably that shown between positions 342 and 720 of SEQ. ID. No. 1. The sequence variant according to the invention may be incorporated in a nucleic acid molecule such that it is operatively linked to a nucleotide sequence. The sequence variant has advantageous properties as a promoter for gene expression, being stronger that the xlnB promoter published in WO 94/14965, and is useful for the expression of a variety of polypeptides, including those encoded by homologous nucleotide sequences such as xylanase B. The invention is particularly useful in the production of substances useful in the foodstuffs, feed and beverage industries. The preferred host, Aspergillus, is a popular production host in these industries, for the reasons set forth hereinbefore. The invention moreover provides a method for increasing the level of transcription of a nucleotide sequence from a promoter, comprising the steps of inserting at least one heterologous copy of the element CGGCAGGGTCTC such that it is operably linked to the promoter, and causing the nucleotide sequence to be transcribed. As used herein, the term "nucleic acid" includes to the natural nucleic acids DNA and RNA, or synthetic nucleic acid analogues which share at least one of the properties of natural nucleic acids, such as the ability to encode a protein or the ability to hybridise to other nucleic acid molecules, preferably natural nucleic acid molecules. The preferred nucleic acid for use in the invention is DNA. Coding sequences may preferably comprise cDNA. References to the element CGGCAGGGTCTC according to the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleotides from or to the sequence providing the resultant nucleotide sequence has the ability to act as an activating element when operatively linked to a promoter in an expression system. In particular, the invention covers homologues of the sequence CGGCAGGGTCTC as evidenced by relative identity in sequence and/or structure and/or function, providing the resultant nucleotide sequence has the ability to act as an activating element according to the invention. With respect to sequence "homology" , preferably there is sequence identity of at least 75 % , more preferably at least 85 % , more preferably at least 90%, to the sequence CGGCAGGGTCTC. More preferably, the element of the invention has no more than 1 , 2 or 3 nucleotide alterations from the sequence CGGCAGGGTCTC. Most preferably, the element has the sequence CGGCAGGGTCTC. The sequences which form part of the present invention may also be in the form of complementary sequences. The term "complementary" means that the present invention also covers nucleotide sequences that can hybridise to the nucleotide sequences of the nucleotide sequence or the promoter sequence, respectively. The element according to the invention is capable of potentiating transcription from a promoter. This means that, in the presence of the element, the potential for transcription is increased. The promoter may remain subject to other influences, such as tissue specific or nutrient-influenced transcriptional regulation, which may so control the transcription from the promoter that no effect is seen with the addition of the element of the invention. However, when such further influences are neutralised, the element will cause an increase in the level of transcription from the promoter. The term "construct" is synonymous with terms such as "conjugate", "cassette" and "hybrid". Constructs may be prepared by linking nucleic acid sequences directly or indirectly, according to techniques known in the art. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Shl-intτon or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. The term "vector" includes expression vectors and transformation vectors. The term "expression vector" means a construct capable of in vivo or in vitro expression of a polypeptide gene product encoded by a coding sequence inserted into the vector. The term "transformation vector" means a construct capable of being transferred from one species to another - such as from an E.coli plasmid to a filamentous fungus, preferably of the genus Aspergillus. As used herein, "vector" refers to discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof. Selection and use of such vehicles are known to those skilled in the art. Many vectors are available, and selection of appropriate vector will depend on the intended use of the vector, i.e. whether it is to be used for DNA amplification or for expression, the size of the DNA to be inserted into the vector, and the host cell to be transformed with the vector. Each vector contains various components depending on its function and the host cell for which it is compatible. The vector components generally include, but are not limited to, one or more of the following: an origin of replication, one or more marker genes, an enhancer element, a promoter, a transcription termination sequence and a signal sequence. Both expression and cloning vectors generally contain at least one nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Typically in cloning vectors, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast and other fungi. The origin of replication from the plasmid pBR322 is suitable for most Gram- negative bacteria, the 2μ plasmid origin is suitable for yeast, and fungal origins may be employed in filamentous fungi, for example the amal replicon (Gems et al. , (1991) Gene 98:61-67). Most expression vectors are shuttle vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For example, a vector is cloned in E. coli and then the same vector is transfected into yeast or other fungal cells even though it is not capable of replicating independently of the host cell chromosome. DNA may also be replicated by insertion into the host genome. Advantageously, an expression and cloning vector may contain a selection gene also referred to as selectable marker which allows for the selection of the genetic construct in, for example, a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, into which it has been transferred. This gene may encode a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin. neomycin, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available from the medium. As to a selective gene marker appropriate for yeast, any marker gene can be used which facilitates the selection for transformants due to the phenotypic expression of the marker gene. Suitable markers for yeast are, for example, those conferring resistance to antibiotics G418, hygromycin or bleomycin, or provide for prototrophy in an auxotrophic yeast mutant, for example the URA3, LEU2, LYS2, TRP1, or HIS3 gene. Since the replication of vectors is conveniently done in E. coli, an E. coli genetic marker and an E. coli origin of replication are advantageously included. These can be obtained from E. coli plasmids, such as pBR322, Bluescript ® vector or a pUC plasmid, e.g. pUC18 or pUC19, which contain both E. coli replication origin and E. coli genetic marker conferring resistance to antibiotics, such as ampicillin. Moreover, the vector according to the invention preferably includes a secretion sequence in order to facilitate secretion of the polypeptide from hosts, such that it will be produced as a soluble native peptide rather than in an inclusion body. Construction of vectors according to the invention employs conventional ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required. If desired, analysis to confirm correct sequences in the constructed plasmids is performed in a known fashion. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing expression and function are known to those skilled in the art. Gene presence, amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA, dot blotting (DNA or RNA analysis), or in situ hybridisation, using an appropriately labelled probe based on a sequence provided herein. Those skilled in the art will readily envisage how these methods may be modified, if desired. The term "host cell", as used herein, includes any cell type, whether a unicellular organism, a cell derived from a multicellular organism and placed in tissue culture or a cell present as part of a multicellular organism, which is susceptible to transformation with a nucleic acid construct according to the invention. Such host cells, such as yeast and higher eukaryote cells, fungal cells and plant cells may be used for replicating DNA and producing polypeptides encoded by nucleotide sequences as used in the invention. Prokaryotic cells are suitable for replicating DNA and include eubacteria, such as Gram- negative or Gram-positive organisms, such as E. coli, e.g. E. coli K-12 strains, DH5α and HBlOl, or Bacilli. Host cells suitable for replicating nucleic acids and expressing coding sequences encoded on vectors according to the invention include eukaryotic microbes such as filamentous fungi, e.g. Aspergillus, or yeast, e.g. Saccharomyce . Particularly preferred are cells from filamentous fungi, preferably Aspergillus, such as A. niger, A. awamori and A. tubingensis. DNA may be stably incorporated into cells or may be transiently expressed using methods known in the art. Stably transfected cells may be prepared by transfecting cells with an expression vector having a selectable marker gene, and growing the transfected cells under conditions selective for cells expressing the marker gene. To prepare transient transfectants, cells are transfected with a reporter gene to monitor transfection efficiency. Host cells are transfected or, preferably, transformed with expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing expression, selecting transformants, or amplifying the genes encoding the desired sequences. Heterologous DNA may be introduced into host cells by any method known in the art, such as transfection with a vector encoding a heterologous DNA by the calcium phosphate coprecipitation technique or by electroporation. Numerous methods of transfection are known to the skilled worker in the field. Successful transfection is generally recognised when any indication of the operation of this vector occurs in the host cell. Transformation is achieved using standard techniques appropriate to the particular host cells used. Incorporation of cloned DNA into a suitable expression vector, transfection of eukaryotic cells with a plasmid vector or a combination of plasmid vectors, each encoding one or more distinct genes or with linear DNA, and selection of transfected cells are well known in the art (see, e.g. Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press) and set forth in particular on pages 15 and 16 herein. Transfected or transformed cells are cultured using media and culturing methods known in the art, preferably under conditions, whereby the polypeptide encoded by the heterologous nucleotide sequence is expressed. The composition of suitable media is known to those in the art, so that they can be readily prepared. Suitable culturing media are also commercially available. The term "organism" in relation to the present invention includes any organism that could express a nucleotide sequence under the control of the promoter according to the present invention. Organisms in which the molecules according to the invention are expressed are preferably fungal hosts. Preferably the organism is a filamentous fungus, preferably of the genus Aspergillus, more preferably A. niger, A. awamori or A. tubingensis. Other preferred organisms include any one of Aspergillus oryzae , Trichoderma reesei, T. viride and T. longibrachiatum. The term "transgenic organism" in relation to the present invention includes any organism that comprises the promoter according to the present invention and a nucleotide sequence coding for a heterologous nucleotide sequence, wherein the nucleotide sequence according to the present invention can be expressed within the organism. Preferably the promoter and the nucleotide sequence are incorporated in the genome of the organism. The term "transgenic organism" does not cover the native nucleotide sequence according to the present invention in its natural environment when it is under the control of its native promoter which is also in its natural environment. In addition, the present invention does not cover the native enzyme according to the present invention when it is in its natural environment and when it has been expressed by its native nucleotide sequence which is also in its natural environment and when that nucleotide sequence is under the control of its native promoter which is also in its natural environment. The transformed cell or organism may be used to prepare acceptable quantities of the desired compound which may be easily retrievable from the cell or organism. The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site in the Jacob-Monod theory of gene expression. Preferably, ungal promoters are used in the present invention. Any suitable promoter may be used in connection with the present invention, with xylan-inducible promoters preferably of fungal origin being especially indicated. A "core" promoter, as referred to herein, in a promoter consisting essentially of a TATA box and a transcriptional initiation site. Fungal promoters are known in the literature (for example, see Gurr, et al , (1987) The structure and organisation of nuclear genes of filamentous fungi. In Kinghorn, J.R. (ed), Gene Structure in Eukaryotic Microbes, IRL Press, Oxford, pp. 93-139). In addition to the nucleotide sequences described above, the promoter of the present invention can additionally include features to ensure or to increase expression in a suitable host. For example, the features can be conserved regions such as a TATA box. The TATA box is typically found 30 bp upstream of the transcription initiation site, and is believed to be involved in the assembly of the transcriptional complex. The promoters may even contain other sequences to affect (such as to maintain, enhance, decrease) the levels of expression of the heterologous nucleotide sequence. Fungal promoters, for instance, typically contain both a TATA box and a UAS (Upstream Activating Site). The UAS is a binding site for the activating regulator acting on the promoter in question. The element of the present invention is believed to be a UAS. Other sites, involved in various aspects of promoter regulation, may also be included. The element of the invention is, according to the present invention, placed upstream of the promoter. The distance between the promoter and the element may be adjusted, by empirical experimentation, to maximise or adjust the level of transcriptional activation. The term "heterologous nucleotide sequence" with reference to the constructs according to the present invention means any sequence encoding a polypeptide of interest, other than the complete natural sequence normally associated with the promoter employed, or a sequence which is capable of expressing a nucleic acid, for example a regulatory RNA such as an antisense RNA or a ribozyme, or a tRNA or rRNA capable of regulating the metabolism of an organism. Conversely, the term "nucleotide sequence" includes homologous nucleotide sequences which are the sequences normally associated with the promoters employed. The invention includes the use of both homologous and heterologous nucleotide sequences. A heterologous nucleotide sequence can be any nucleotide sequence that is either foreign or natural to the organism (e.g. filamentous fungus, preferably of the genus Aspergillus, or a plant) in question. The term "heterologous nucleotide sequence" also includes a homologous nucleotide sequence which has been mutated, such as by insertion, addition, deletion or alteration, such that it is no longer identical with the natural homologous nucleotide sequence. Typical examples of a heterologous nucleotide sequence include sequences coding for proteins and enzymes that modify metabolic and catabolic processes. The heterologous nucleotide sequence may code for an agent for introducing or increasing pathogen resistance. The heterologous nucleotide sequence may be an antisense construct for modifying the expression of natural transcripts present in the relevant tissues. The heterologous nucleotide sequence may code for a non-native protein of a filamentous fungus, preferably of the genus Aspergillus, or a compound that is of benefit to animals or humans. Examples of nucleotide sequences encoding enzymes include pectinases, pectin depolymerases, polygalacturonases, pectate lyases, pectin lyases, hexose oxidase, oxidoreductases, Upases, glucan lyase, rhamno-galacturonases, hemicellulases, endo-β- glucanases, arabinases, or acetyl esterases, or combinations thereof, as well as antisense sequences thereof. The heterologous nucleotide sequence may be a protein giving nutritional value to a food or crop. Typical examples include plant proteins that can inhibit the formation of anti-nutritive factors and plant proteins that have a more desirable amino acid composition (e.g. a higher lysine content than a non-transgenic plant). The heterologous nucleotide sequence may code for an enzyme that can be used in food processing such as chymosin, thaumatin, α-galactosidase, a glucanase or β-1,4- endoglucanase. The heterologous nucleotide sequence may code for an intron of a particular nucleotide sequence, wherein the intron can be in sense or antisense orientation. The heterologous nucleotide sequence can be the nucleotide sequence coding for the arabinofuranosidase enzyme which is the subject of PCT patent application PCT/EP96/01009 (incorporated herein by reference). The heterologous nucleotide sequence can be any of the nucleotide sequences coding for the ADP-glucose pyrophosphorylase enzymes which are the subject of PCT patent application PCT/EP94/01082 (incorporated herein by reference). The heterologous nucleotide sequence can be any of the nucleotide sequences coding for the α-glucan lyase enzyme which are described in PCT patent application PCT/EP94/03397 (incorporated herein by reference). The heterologous nucleotide sequence can be any of the sequences coding for T. lanuginosus amylase, as described in PCT patent application PCT/EP95/02607, incorporated herein by reference. The heterologous nucleotide sequence can be any of the nucleotide sequences coding for the glucanase enzyme which are described in PCT patent application PCT/EP96/01008 (incorporated herein by reference). The heterologous nucleotide sequence can be xylanase A or B, as set forth herein. Preferably the promoter and the nucleotide sequence according to the invention are stably maintained within host cells or transgenic organisms. By way of example, the promoter and/or the nucleotide sequence may be maintained within the transgenic organism in a stable extrachromosomal construct. This is preferred for transgenic yeast or some filamentous fungi. Alternatively, the promoter and/or the heterologous nucleotide sequence (such as the nucleotide sequence according to the present invention) may be stably incorporated within the transgenic organism's genome. This is preferred for some transgenic yeast, and most filamentous fungi. A preferred host organism for the expression of the nucleic acid constructs of the present invention and/or for the preparation of the heterologous polypeptides according to the present invention is an organism of the genus Aspergillus, such as Aspergillus niger. In this regard, a transgenic Aspergillus according to the present invention can be prepared by following the teachings of Rambosek, J. and Leach, J. 1987 (Recombinant DNA in filamentous fungi: Progress and Prospects. CRC Crit. Rev. Biotechnol. 6:357-393), Davis R.W. 1994 (Heterologous gene expression and protein secretion in Aspergillus . In: Martinelli S.D., Kinghorn J.R. (Editors) Aspergillus: 50 years on. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp 525-560), Ballance, D.J. 1991 (Transformation systems for Filamentous Fungi and an Overview of Fungal Gene structure. In: Leong, S.A., Berka R.M. (Editors) Molecular Industrial Mycology. Systems and Applications for Filamentous Fungi. Marcel Dekker Inc. New York 1991. pp 1-29) and Turner G. 1994 (Vectors for genetic manipulation. In: Martinelli S.D., Kinghorn J.R. (Editors) Aspergillus: 50 years on. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666). The following commentary provides a summary of those teachings for producing transgenic Aspergillus according to the present invention. For almost a century, filamentous fungi have been widely used in many types of industry for the production of organic compounds and enzymes. For example, traditional Japanese koji and soy fermentations have used Aspergillus sp. Also, in this century Aspergillus niger has been used for production of organic acids particular citric acid and for production of various enzymes for use in industry. There are two major reasons why filamentous fungi have been so widely used in industry. First filamentous fungi can produce high amounts of extracelluar products, for example enzymes and organic compounds such as antibiotics or organic acids. Second filamentous fungi can grow on low cost substrates such as grains, bran, beet pulp etc. The same reasons have made filamentous fungi attractive organisms as hosts for heterologous expression according to the present invention. In order to prepare the transgenic Aspergillus, expression constructs are prepared by inserting a heterologous nucleotide sequence (such as a nucleotide sequence coding for an amylase enzyme) into a construct designed for expression in filamentous fungi. Several types of constructs used for heterologous expression have been developed. The constructs contain the promoter according to the present invention which is active in fungi. The heterologous nucleotide sequence can be fused to a signal sequence which directs the protein encoded by the heterologous nucleotide sequence to be secreted. Usually a signal sequence of fungal origin is used. A terminator active in fungi may also be employed. Another type of expression system has been developed in fungi where the heterologous nucleotide sequence is fused to a fungal gene encoding a stable protein. This can stabilise the protein encoded by the heterologous nucleotide sequence which encodes a protein of interest (POI). In such a system a cleavage site, recognised by a specific protease, can be introduced between the fungal protein and the protein encoded by the heterologous nucleotide sequence, so the produced fusion protein can be cleaved at this position by the specific protease thus liberating the protein encoded by the heterologous nucleotide sequence. By way of example, one can introduce a site which is recognised by a KEX-2 like peptidase found in at least some Aspergilli (Broekhuijsen et al 1993 J Biotechnol 3_i 135-145). Such a fusion leads to cleavage in vivo resulting in protection of the expressed product and not a larger fusion protein (see US 5,679,543). Heterologous expression in Aspergillus has been reported for several genes coding for bacterial, fungal, vertebrate and plant proteins. The proteins can be deposited intracellularly if the nucleotide sequence according to the present invention (or another heterologous nucleotide sequence) is not fused to a signal sequence. Such proteins will accumulate in the cytoplasm and will usually not be glycosylated which can be an advantage for some bacterial proteins. If the nucleotide sequence according to the present invention (or another heterologous nucleotide sequence) is equipped with a signal sequence the protein will accumulate extracelluarly. With regard to product stability and host strain modifications, some heterologous proteins are not very stable when they are secreted into the culture fluid of fungi. Most fungi produce several extracelluar proteases which degrade heterologous proteins. To avoid this problem special fungal strains with reduced protease production have been used as host for heterologous production. For the transformation of filamentous fungi, several transformation protocols have been developed for many filamentous fungi (Ballance, D.J. 1991 (Transformation systems for Filamentous Fungi and an Overview of Fungal Gene structure. In: Leong, S.A., Berka R.M. (Editors) Molecular Industrial Mycology. Systems and Applications for Filamentous Fungi. Marcel Dekker Inc. New York 1991. pp 1-29). Many of them are based on 2 + preparation of protoplasts and introduction of DNA into the protoplasts using PEG and Ca ions. The transformed protoplasts then regenerate and the transformed fungi are selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as argB, trpC, niaD and pyrG, antibiotic resistance markers such as benomyl resistance, hygromycin resistance and phleomycin resistance. A commonly used transformation marker is the amdS gene of A. nidulans which in high copy number allows the fungus to grow with acrylamide as the sole nitrogen source. In another embodiment the transgenic organism can be a yeast. In this regard, yeast have also been widely used as a vehicle for heterologous gene expression. The species Saccharomyces cerevisiae has a long history of industrial use, including its use for heterologous gene expression. Expression of heterologous genes in Saccharomyces cerevisiae has been reviewed by Goodey et al (1987, Yeast Biotechnology, D R Berry et al, eds, pp 401-429, Allen and Unwin, London) and by King et al (1989, Molecular and Cell Biology of Yeasts, E F Walton and G T Yarranton, eds, pp 107-133, Blackie, Glasgow). For several reasons Saccharomyces cerevisiae is well suited for heterologous gene expression. First, it is non-pathogenic to humans and it is incapable of producing certain endotoxins. Second, it has a long history of safe use following centuries of commercial exploitation for various purposes. This has led to wide public acceptability. Third, the extensive commercial use and research devoted to the organism has resulted in a wealth of knowledge about the genetics and physiology as well as large-scale fermentation characteristics of Saccharomyces cerevisiae. A review of the principles of heterologous gene expression in Saccharomyces cerevisiae and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", Yeasts, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.). Several types of yeast vectors are available, including integrative vectors, which require recombination with the host genome for their maintenance, and autonomously replicating plasmid vectors. In order to prepare the transgenic Saccharomyces, expression constructs are prepared by inserting a nucleotide sequence comprising a DNA construct according to the present invention into a construct designed for expression in yeast. Several types of constructs used for heterologous expression have been developed, suitable component parts of which are discussed hereinbefore. For the transformation of yeast several transformation protocols have been developed. For example, a transgenic Saccharomyces according to the present invention can be prepared by following the teachings of Hinnen et al (1978, Proceedings of the National Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H et al (1983, J Bacteriology 153, 163-168). The following sequences are set forth in the Sequence Listing: SEQ. ID. No. 1 A. tubingensis Xylanase B SEQ. ID. No. 2 A. tubingensis Xylanase B amino acid sequence SEQ. ID. No. 3 The A. tubingensis Xylanase B promoter region SEQ. ID. No. 4 The Xylanase A gene SEQ. ID. No. 5 The amyA gene SEQ. ID. No. 6 The complete nucleotide sequence of pPR70 SEQ. ID. No. 7 - 15 Synthetic DNA oligonucieotide primers Deposition Data The following deposits have been made under the Budapest Treaty in connection with the present application at the NCIMB, 23 St. Machar Drive, Aberdeen, AB2 1RY, Scotland: E. coli DH5α pXylA Accession No. 40861 Deposited 20.2.1997 E. coli DH5α pXylB Accession No. 40862 Deposited 20.2.1997 E. coli DH5α px/nB-AmyA Accession No. 40858 Deposited 31.1.1997 The invention is described hereinbelow, for the purposes of illustration only, with reference to the following examples, in which reference is made to the following figures. Figure 1 shows plasmid pxlnB-AmyA, which comprises the xlnB promoter, the amyA gene and the xlnA terminator, together with an ampicillin resistance selection marker. Figure 2 shows a mono-Q chromatogram of the culture broth of A. niger transformed with pxlnB-AmyA. Figure 3 shows plasmid LMJterm. Figure 4 shows plasmid pPR66. Figure 5 shows plasmid pPR67. Figure 6 shows plasmid pPR68. Figure 7 shows plasmid pPR69. Figure 8 shows plasmid pPR70. Figure 9 shows a silver-stained gel of the products derived from A. niger transformed with pPR70 and pPR70-6. Figure 10 shows a plot of the results of the cultivation of tubingensis transformed with a xlnB-xlnA expression construct. Example 1: Preparation of xlήB-amyA-xlnA construct. Basic molecular manipulation is performed according to established techniques such as those described in: J. Sambrook, et al, Molecular Cloning. A Laboratory Manual. Second Edition, Cold Spring Harbour Press, New York 1989. Restriction enzymes are used according to the instructions supplied by the manufacturer (New England Biolabs Ltd. and Amersham Ltd.) pXYLA containing the xlnA gene (SEQ. ID. No. 4) is digested with BamHI and Xbal and the 1081 bp fragment containing the xlnA terminator is purified and inserted into a BamHI-Xbal digested pBluescriptllSK-r- vector. The resulting vector is called pPR15. pXYLB containing the entire xlnB gene (SEQ. ID. No. 1) is digested with Nspl and blunt ended with Mung Bean Nuclease. The nuclease is inactivated by heat treatment 15 min 65 ' C, whereafter the DNA is digested with Clal, and a fragment of 377 bp containing the xlnB promoter is purified. pPR15 is digested with EcoRI and the postruding ends are completely filled in using Klenow polymerase. The enzyme is heat inactivated 15 min 75 'C, and the vector digested with Clal. The purified promoter is inserted into the digested vector and the resulting plasmid pPR42 is obtained. pAMYA-3 (See PCT/EP95/02607; deposited under accession no. NCIMB 40657) containing amyA (SEQ. ID. No. 5), encoding the -amylase of T. lanuginosus is digested with Seal and Ecll36II and a 2106p fragment containing the complete amyA gene is purified and inserted into pPR42 digested with Smal and dephosphorylated with Calf Intestinal phosphatase. A transforming with the correct orientation of the gene is identified by restriction analysis and the resulting plasmid is named px/nB-AmyA (Figure 1) The xlnB promoter corresponds to nucleotide 342-720 of the sequence in SEQ. ID. No. 1. The amyA gene corresponds to nucleotide 406-2512 of the sequence in SEQ. ID. No. 5 The xlnA terminator corresponds to nucleotide 1883-2962 of the sequence in SEQ. ID. No. 4. Example 2: Transformation of the construct in Aspergillus awamori The xlnB-amyA-xlnA construct is transformed into A. awamori, generally obtainable from the ATCC under accession no. 11358, by the following protocol (see also WO 96/29415) using cotransformation with a Hygromycin resistance marker (Werners, K. et al (1987) Molecular and General Genetics 209, 71-77). The protocol for transformation of A. awamori is based on the teachings of Buxton, F.P., Gwynne D.I., Davis, R.W. 1985 (Transformation of Aspergillus niger using the argB gene of Aspergillus nidulans. Gene 37:207-214), Daboussi, M.J., Djeballi, A., Gerlinger, C, Blaiseau, P.L., Cassan, M., Lebrun, M.H., Parisot, D., Brygoo,Y. 1989 (Transformation of seven species of filamentous fungi using the nitrate reductase gene of Aspergillus nidulans. Curr. Genet. 15:453-456) and Punt, P.J., van den Hondel, C.A.M.J.J. 1992 (Transformation of filamentous fungi based on hygromycin B and Phleomycin resistance markers. Meth. Enzym. 216:447-457). For the purification of protoplasts, spores from one PDA (Potato Dextrose Agar - from Difco Lab. Detroit) plate of fresh sporulated N400 (CBS 120.49, Centraalbureau voor Schimmelcultures, Baarn) (7 days old) are washed off in 5-10 ml water. A shake flask with 200 ml Potato Dextrose Broth (Difco 0549-17-9, Difco Lab. Detroit) is inoculated with this spore suspension and shaken (250 rpm) for 16-20 hours at 30°C. The mycelium is harvested using Miracloth (Nylon ® mesh) and 3-4 g wet mycelium are transferred to a sterile petri dish with 10 ml STC (1.2 M sorbitol, 10 mM Tris HC1 pH 7.5, 50 mM CaCl 2 ) with 75 mg lysing enzymes (Sigma L-2265) and 4500 units lyticase (Sigma L-8012). The mycelium is incubated with the enzyme until the mycelium is degraded and the protoplasts are released. The degraded mycelium is then filtered through a sterile 60 μm mesh filter. The protoplasts are harvested by centrifugation 10 min at 2000 rpm in a swing out rotor. The supernatant is discarded and the pellet is dissolved in 8 ml 1.5 M MgSO 4 and then centrifuged at 3000 rpm for 10 min. The upper band, containing the protoplasts is transferred to another tube, using a transfer pipette and 2 ml 0.6 M KC1 is added. Carefully 5 ml 30% sucrose is added on the top and the tube is centrifuged 15 min at 3000 rpm. The protoplasts, lying in the interface band, are transferred to a new tube and diluted with 1 vol. STC. The solution is centrifuged 10 min at 3000 rpm. The pellet is washed twice with STC, and finally solubilised in 1 ml STC. The protoplasts are counted and eventually concentrated before transformation. For the transformation, 100 μl protoplast solution (10 6 -10 7 protoplasts) are mixed with 10 μl DNA solution containing 5-10 μg DNA and incubated 25 min at room temperature. Then 60 % PEG-4000 is carefully added in portions of 200 μl, 200 μl and 800 μl. The mixture is incubated 20 min at room temperature. 3 ml STC is added to the mixture and carefully mixed. The mixture is centrifuged 3000 rpm for 10 min. The supernatant is removed and the protoplasts are solubilised in the remaining of the supernatant. 3-5 ml top agarose is added and the protoplasts are quickly spread on selective plates. Transformed colonies subsequently picked and grown up as set forth below. Example 3: Analysis of transformants Hygromycin resistant transformants are grown in minimal medium containing basal inorganic salts, 0,5 % Glucose, 0,5 % oat spelt xylan and 50 mM MES pH 6.0, at 30 'C shaking 250 rpm. After 5 days of growth culture samples are analysed for α- amylase using the Ceralpha substrate (MegaZyme, Australia). One vial of Ceralpha is dissolved in 10 ml water to get the useable substrate. The analysis is performed in microtiter wells. In each well 175 μl buffer (50mM Citrate buffer pH 6.2, 5 mM CaCl 2 «2H 2 O), 25 μl sample (Diluted in buffer if necessary) and 50 μl Ceralpha substrate is mixed and the reaction mixture is incubated 15 min at 37 ° C. The reaction is stopped by transferring 100 μl of the reaction to 150 μl 1 % Trizma base in a new microtiter well. Activity is measured as a rise in OD 420 measured in an Elisa reader. The best producing transformants are grown in shake flasks in a medium composed of 2% beet pulp, 2% wheat bran, 0,3 % NaN0 3 , 100 mM MES pH 5.5. The cultures are grown for 5-7 days at 30 ° C with shaking 250 rpm. The activity is measured and surprisingly more than 1 g/1 of T. lanuginosus - amylase is obtained. A Mono-Q chromatogram is shown in figure 2, and was performed as follows. A sample of a culture broth in which a transformant organism has been grown is filtered through a 0.45μm filter. 1.5ml of the filtrate is applied to a PD-10 column (Pharmacia, Sweden) equilibrated with lOmM triethanolamine pH 7.0 (Buffer A), and eluted with 2.5ml Buffer A. 1ml of the eluate is loaded on a Mono-Q HR5/5 column (Pharmacia) equilibrated with Buffer A. The column is washed with Buffer A until the base line is stable. The proteins bound to the column are than eluted using a salt gradient of 0 to 0.5M NaCl in Buffer A. The eluted proteins are detected at OD 280 . Example 4: Construction of an expression vector containing the xlnB promoter. A vector for analysis of the xlnB promoter is constructed as follows. The vector pLMJterm containing a fungal terminator in a pBluescriptSKII+ (Stratagene), which is constructed by inserting the egl B gene terminator fragment located between positions 2330 and 2823 of SEQ. ID. No. 16 of PCT/EP97/04415 (derived from GB 9617184.8, published 15th February 1998) into pBluescript, is digested with Kpnl. The extensions are removed using T4 DNA polymerase and following the blunt ended vector is religated to give the plasmid pPR66. pXYLB is digested with Clal and Nspl and a fragment of 382 nucleotides containing the xlnB promoter is purified. This fragment is treated with T4 DNA polymerase to remove extensions and subsequently ligated into pPR66, digested with Smal and dephosphorylated using calf intestinal phosphatase. Plasmids are purified from transformants and digested with Xbal to isolate the desired plasmid where the xlnB promoter transcribes towards the terminator. Such a plasmid is isolated and named pPR67. This plasmid is an expression vector containing the xlnB promoter and a functional fungal terminator. In order to insert a reporter gene in the expression vector, pAMYA-1 (WO 96/01323) is digested with Seal and Ecll36II and a fragment of 2106 nucleotides comprising the amyA gene is purified, as in Example 1. pPR67 is digested with Clal and EcoRI, blunt-ended using Klenow polymerase, and dephosphorylated using Calf intestinal phosphatase. The purified fragment containing amyA is ligated into pPR67 treated in this manner. A recombinant plasmid with the amyA gene in the correct orientation is found by restriction analysis using Ncol. This plasmid is named pPR68. pPR68 is a expression vector with the xlnB promoter controlling the expression of α-amylase from amyA. In the xlnB promoter a unique Kpnl site is located in which additional copies of the xlnB element can be inserted. Next a selective marker gene pyrG is inserted into the vector. Unfortunately this gene contains a Kpnl site which means that the Kpnl site in the promoter will not be unique. Therefore the Kpnl site of pPR68 is converted into a SnaBI site. pPR68 is digested with Acc65I (which recognises the same site as Kpnl but give 5 ' extension ends instead of 3' extension ends) and the ends are filled in using Klenow polymerase. The vector is religated and the Kpnl site is converted into a SnaBI Site. This vector is called pPR69. Finally, a pyrG selection marker is inserted into the plasmid. A Xbal-Hindlll fragment of 1517 nucleotides is purified from pAB4-l (van Hartingsveldt et al. , Mol. Gen. Genet. (1987) 206: 71-75). The fragment is treated with Klenow polymerase in order to blunt the ends. pPR69 is digested with BamHI and treated with Klenow polymerase. The purified and modified fragment is ligated into the digested and treated vector, and a recombinant vector called pPR70 is isolated. pPR70 is the desired expression vector. It contains a reporter gene amyA under control of the xlnB promoter, a unique SnaBI site is convenient located in the promoter into which additional copies of the xlnB element can be inserted, and finally a selection marker pyrG is included which allows integration of the plasmid and variants into the pyrG locus which makes the comparison more reliable. The complete sequence of pPR70 is given in SEQ. ID. No. 6. Example 5: Construction of expression vectors containing derivatives of the xlnB promoter The following oligonucleotides are synthesised on a Applied Biosystems 392 DNA/RNA synthesiser: sense CGG CAG GGT CTC (SEQ. ID. No. 7) antisense GAG ACC CTG CCG (SEQ. ID. No. 8) Annealing of oligonucleotides: 100 pmol of each oligonucieotide is mixed in a tube in a total volume of 20 μl. The tube is heated for 2 min at 70 °C and allowed to cool slowly to room temperature. The annealed oligonucleotides are stored at -20 and kept on ice at use. 5 pmol of the annealed oligonucieotide is ligated with approximately 100 ng pPR70 digested with SnaBI. After ligation the reaction is digested with SnaBI to avoid pPR70 from religating without insert. Transformants which have lost the SnaBI site are analysed by sequencing. The following primer is designed for sequencing: TCG ACT GAG CTT TCC ACT CAT (SEQ. ID. No. 9). The primer is Cy5 labelled in the 5' end to be used for sequencing in an ALF sequencer (Pharmacia). The primer binds to the amyA gene (position 5407-5427 in pPR70) and sequencing from the primer reads through the xlnB promoter. By sequencing, a number of derivatives of pPR70 with modified number of xlnB copies are identified: pPR70 tacgtacctgccGAGACCCTGCCGAGACCCTGCCG aggccctaaatgt GAGACCCTGCCG tac (SEQ. ID. No. 10) pPR70-6 tacGAGACCCTGCCG aggccctaaatgt GAGACCCTGCCG tac (SEQ. ID. No. 11) pPR70-16 tacGAGACCCTGCCGAGACCCTGCCG aggccctaaatgt GAGACCCTGCCG tac (SEQ. ID. No. 12) pPR70-3 tacGAGACCCTGCCG gtacctgcc GAGACCCTGCC GAGACCCTGCCG aggccctaaatgt GAGACCCTGCCG tac (SEQ. ID. No. 13) pPR70-5 tac GAGACCCTGCCG GAGACCCTGCCG gtacctgcc GAGACCCTGCC GAGACCCTGCCG aggccctaaatgt GAGACCCTGCCG tac (SEQ. ID. No. 14) pPR70-4 tac GAGACCCTGCCG CGGCAGGGTCTC CGGCAGGGTCTC gtacctgcc GAGACCCTGCCGAGACCCTGCCG aggccctaaatgt GAGACCCTGCCG tac (SEQ. ID. No. 15) The lowercase letters represent the sequences between the xlnB elements. The uppercase letters are the xlnB elements. Note that due to the positioning of the sequencing primer site, the sequences are derived from the - strand. An alignment of the complementary (+ strand) sequences, which correspond to the sequences shown in the SEQ. IDs., is shown in Table 1. All the sequences start at the SnaBI site of pPR70 (position 5661) or the corresponding site in which additional elements have been inserted. In the constructs where a deletion is observed is the most likely explanation is that an element has inserted, and a recombination event has subsequently occurred between two xlnB elements where some nucleotides have been lost, creating the observed deletions. The variants can be described in the following way: pPR70-6 a xlnB element has been deleted as well as 9 nucleotides next to the elements. Only two elements are retained in this plasmid. pPR70-16 9 nucleotides next to xlnB elements have been deleted. Three elements are in this construct. pPR70-3 one xlnB element has been added so that four xlnB elements are present in this construct. pPR70-5 two elements have been added giving five xlnB elements in this construct. pPR70-4 Three elements have been added. Of these one is in the same orientation as the native xlnB elements. The other two are in the opposite orientation. Example 6: Transformation of the constructs in Aspergillus niger Plasmid pPR70 and its derivatives are transformed into A. niger AB6-4, obtained from Dr. P. Punt, Netherlands Organisation for Applied Scientific Research (TNO), Nutrition and Food research Institute, Biochemistry and Gene Technology, Zeist, The Netherlands, by the following protocol (see also WO 96/29415). The protocol for transformation of A. niger is based on the teachings of Buxton, F.P., Gwynne D.I., Davis, R.W. 1985 (Transformation of Aspergillus niger using the argB gene of Aspergillus nidulans. Gene 37:207-214), Daboussi, M.J., Djeballi, A., Gerlinger, C, Blaiseau, P.L., Cassan, M., Lebrun, M.H., Parisot, D., Brygoo,Y. 1989 (Transformation of seven species of filamentous fungi using the nitrate reductase gene of Aspergillus nidulans. Curr. Genet. 15:453-456) and Punt, P.J., van den Hondel, C.A.M.J.J. 1992 (Transformation of filamentous fungi based on hygromycin B and Phleomycin resistance markers. Meth. Enzym. 216:447-457). Aspergillus niger AB6-4 (pyrG, ΔglaA, fwnA) is used as the expression host. AB6-4 is grown on Potato dextrose agar (PDA, Difco Labs. Detroit) for 5-7 days until the conidia are formed. Conidia are then washed form the culture with 10 ml ST (0.8% Sodium chloride, 0.05% Tween-20). A 500 ml shake flask containing 200 ml rich medium is inoculated with 10 6 conidia /ml and grown for 20 h at 30 °C with shaking. The mycelium is harvested and washed with 1 % NaCl. approximately 1 g wet weight mycelium is transferred to a 300 ml shake flask together with 20 ml SMC (1.33M Sorbitol, 50 mM CaCl 2 , 20 mM MES buffer pH 5.8) and 150 mg lysine enzyme (Sigma no. L2265) and incubated at 37 °C until protoplasts are released (1-3 hours). Protoplasts are purified by filtration through glass wool in a 20 ml syringe. In this filtration the protoplasts passes through the glass wool filter, whereas the mycelium debris remains in the filter. Table 1 Alignment of pPR70 and variants among the xlnB elements. The start of the sequences is the SnaBI site (5661) into which the elements are inserted Wild type gta CGGCAGGGTCTC acatttagggcct CGGCAGGGTCTCGGCAGGGTCTC ggcaggtac gta pPR70-6 gta CGGCAGGGTCTC acatttagggcct CGGCAGGGTCTC gta pPR70-16 gta CGGCAGGGTCTC acatttagggcct CGGCAGGGTCTCGGCAGGGTCTC gta pPR70-3 gta CGGCAGGGTCTC acatttagggcct CGGCAGGGTCTCGGCAGGGTCTC ggcaggtac CGGCAGGGTCTC gta pPR70-5 gta CGGCAGGGTCTC acatttagggcct CGGCAGGGTCTCGGCAGGGTCTC ggcaggtac CGGCAGGGTCTC CGGCAGGGTCTC gta pPR70-4 gta CGGCAGGGTCTC acatttagggcct CGGCAGGGTCTCGGCAGGGTCTC ggcaggtac CGGCAGGGTCTC (GAGACCCTGCCG) 2 gta ro a . The enzymatic solution containing protoplasts is centrifuged at 2500 rpm for 10 min in a Hettisch universal 30 F centrifuge. The pellet containing the protoplast is then dispersed in 10 ml STC (1.33 M Sorbitol, 50 mM CaCl 2 , 10 mM Tris-HCl pH 7.5) and centrifuged again. This wash is repeated. Finally the protoplasts are dispersed in 1 ml STC and counted. The protoplast suspension is diluted with STC to a final concentration of 5 x 10 protoplasts per ml. To transform the protoplasts 100 μl protoplast suspension is mixed with 1-10 μg plasmid DNA and incubated for 25 min at room temperature. Aliquots of 200, 200 and 850 μl PEG buffer (60 % PEG-4000, 10 mM Tris-HCl, 50 mM CaCl 2 ) are added, and after each addition the mixture is carefully mixed. The mixture is then incubated for 20 min at room temperature. The protoplasts are then washed 2-3 times with 8 ml STC and finally dispersed into approximately 0.5 ml STC. 4 ml melted top agarose, prepared to the same formulation as the selective plates (see below) but employing 0.6% agarose in place of agar, cooled to 46 °C, is added to the 0.5ml suspension and the mixture is immediately poured onto selection plates for selection of transformants. After incubation for 4-6 days at 30 °C transformants emerge and are recultivated on minimal plates. Rich Medium is prepared in the following way: per litre: 100 ml Basal salt solution 1 ml Trace element solution (Vishniak's solution: Vishniac, W. and Santer M. (1957) The Thiobaccilli. Bacteriol. Rev. 21:195-213) 10 ml 1 M (NH 4 ) 2 SO 4 After autoclaving 200 ml is transferred to a 500 ml sterile shake flake and 20 ml 20% glucose, 20 ml 2% casein hydrolysate and 10 ml 5% yeast extract is added, under sterile conditions. Selective plates per litre 100 ml Basal salt solution 1 ml Trace element solution (Vishniak's solution) 10 ml 1 M (NH 4 ) 2 SO 4 219 g Sorbitol (= 1.2 mol) 20 g glucose (Can be omitted when sorbitol is present) 20 g agar The solution for autoclaved 20 min at 120 °C, cooled to 60 °C and poured into petri dishes. Minimal plates are prepared in the same by but without sorbitol. Basal Salt solution, per litre: 5 g KC1 5 g MgSO 4 7H 2 O 15 g NaH 2 PO 4 1 g CaCl 2 Example 7 Determination of integration locus and copy number Total DNA is extracted from the transformants by the following procedure: Approximately 0.5 g mycelium is harvested and transferred to an Eppendorf tube. 200 μl glass beads (diameter 1 mm) and 0.5 ml extraction buffer (100 mM Tris-HCl pH 8.0 50 mM disodium ethylenediamino tetraacetate (EDTA), 500 mM NaCl 1 mM dithiothreitol) is added and the mycelium is homogenised for 30 s in a Mini Bead Beater (Biospec inc.). 50 μl 20 % SDS (sodium dodecylsulphate) is added and the tubes are incubated for 10 min at 65 °C. 100 μl 5 M KAc (prepared according to Sambrook et al.) is added and the mixture is incubated for 10 min on ice. After centrifugation for 10 min at 15000g, 900 μl supernatant is transferred to a new tube containing 550 μl isopropanol, and DNA is precipitated by incubation for 15 min on ice. DNA is harvested by centrifugation for 10 min at 15000g, and resolubilised in 200 μl TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA). The solution is extracted once with 200 μl phenol/chloroform (1: 1) equilibrated with TE and precipitated by addition of 20 μl 3M NaAc pH 4.8 and 500 μl ethanol. The DNA is harvested by centrifugation for 10 min at 15000g, washed with 70 % ethanol and dried. Finally the DNA is resolubilised in 50 μl TE. Southern blot ca. 5 μg of each DNA preparation is digested with EcoRI in a total volume of 100 μl for 4 hours. The DNA is precipitated and dissolved in 20 μl TE. The digested samples are run on a 1 % agarose gel with 1 x TBE as running buffer. As molecular weight markers, S DNA a commercial molecular weight marker (22Kb-0.06 Kb from Amersham) is used. After the gel is run the DNA is depurinated, denatured and transferred to an Hybond-N hybridisation membrane (Amersham) according to the instructions by the manufacturer. After the transfer the DNA is fixed by UV crosslinking. The hybridisation probe is prepared by digestion of pPR70 with Ncol and purification of a fragment of ca. 2000 bp. The purified fragment is labelled using Ready-To-Go labelling kit (Pharmacia) using deoxycytidine-5'(α- 32 P)-triphosphate, triethylammonium salt — 3000 Ci/mmol (Amersham). The hybridisation is performed according to the instructions of the manufacturer of the hybridisation membranes at high stringency using a washing temperature of 65 °C and following washes 2 x SSC, 0.1 % SDS, twice, for 15 min, 1 x SSC, 0.1 % SDS for 15 min and 0.1 x SSC, 0.1 % SDS for 10 min. The membranes are exposed overnight Transformants giving rise to hybridisations at fragments of 6000 and 1000 bp contain single copy integrated plasmids in the pyrG locus and these transformants are used in the following experiments. Transformants giving rise to other combinations of hybridisations are discarded. Example 8 Growth experiment of single copy transformants The selected transformants are grown in 100 ml of the following medium in 300 ml shake flasks: Per litre 100 ml Basal salt solution 1 ml Trace element solution (Vishniak's solution) 10 ml 1 M (NH 4 ) 2 SO 4 14.7 g triSodium citrate After autoclaving, 100 ml 20% xylose and 100 ml 2% casein hydrolysate is added, under sterile conditions. 10 ml 100 mM uridine is added to the control flask in view of AB 6-4 's uridine requirement, satisfied by the vector in the transformants. The flasks are inoculated with 10 5 spores per ml and incubated in an orbital shaker at 30°C. After 64 hours the α-amylase activities of the supernatants are analysed, as follows: α-amylase activities are measured in microtiter plates. 175 μl buffer (50 mM citrate buffer, pH 6.5, 5 mM CaCl 2 ) are mixed with 25 μl sample in each well. The reaction is started by addition of 50 μl Ceralpha substrate (MegaZyme, Canberra, Australia) to the well. The plate is incubated at 37 °C. After 15 and 30 minutes 100 μl of the reaction is transferred to a new well containing 150 μl stop buffer (1 % trizma base). The substrate is a chromogenic substrate which is composed of a heptamaltose where nitrophenyl is coupled to the reducing end, and the nonreducing end is blocked by another group. Upon digestion of an internal αl,4 bond α-glucosidases which are included into the substrate degrade the now unblocked substrate and release the yellow compound p-nitrophenol. The activity is measured in an Elisa reader at wavelength 405 nm. The activity calculated as the rise in absorbance in 15 min. The following results are obtained: Table 2 α-amylase activity experiment 1 experiment 2 average Aspergillus niger AB6-4 0.137 0.097 0.117 AB6-4: :pPR70 2.816 2.909 2.863 AB6-4: :pPR70-6 0.440 0.273 0.356 AB6-4::pPR70-16 2.725 2.907 2.816 AB6-4::pPR70-3 1.005 0.749 0.877 AB6-4::pPR70-5 0.872 0.872 AB6-4: :pPR70-4 0.307 0.159 0,233 These results show that there is a optimal number of xlnB elements of three. Deletion of one element gives a 6 fold reduction in activity. When more elements are added the activity drops more progressively. Example 9: Growth of Aspergillus niger AB6-4 transformants with pPR70 and pPR70-6 The untransformed host A. niger AB6-4 and transformants with a single copy of pPR70 and pPR70-6 integrated therein, as determined in example 8, are grown in 100 ml of the following medium in 300 ml shake flasks: Per litre 100ml Basal salt solution 1 ml Trace element solution (Vishniak's solution) 10 ml 1 M (NH 4 ) 2 SO 4 14.7 g triSodium citrate After autoclaving, 100 ml 20% xylose and 100 ml 2% casein hydrolysate is added under sterile conditions. lOmM uridine is added to the flask containing the untransformed host. The flasks are inoculated with 10 spores per ml and incubated in an orbital shaker at 30°C. After 64 hours α-amylase activities of the supernatants are analysed according to example 6 and high α-amylose activity is found in the flask with the transformed fungus whereas no activity is found in the flask containing the untransformed host. For visualisation of the results, 5 and 20 μl of the culture broth is loaded on a precast 12 % Tris-Glycine gel (NOVEX, San Diego, CA) according to the instructions supplied by the manufacturer. As a molecular weight marker, a commercially available low molecular weight marker 14.4-94 KD (Pharmacia) is used. The gel is silver stained. In the untransformed host only very weak bands are visible. In the transformant in addition to the weak bands seen in the untransformed host a strong band appears at 54 KD which corresponds the mobility of Thermomyces lanuginosus α-amylase. The strength of this band is reduced, almost to invisibility, in pPR70-6 (See Figure 9). Silver staining procedure: -After electrophoresis the gel is soaked in 50% Ethanol, 12% acetic acid, 0.05% of 37% formaldehyde for one hour or more to fix the proteins. -The gel is washed in 50 % ethanol three times for 20 min. -Soaked 1 min in 0.2 g/1 Na 2 SO 3 .5H2O. -Washed 3 times for 20 seconds in water. -Soaked in 2g/l AgNO 3 , 750 μl of 37 % formaldehyde for 20 min. -Washed two times for 20 seconds in water. -Colour is developed in (per litre: 60g Na 2 CO 3 , 500 μl of 37% formaldehyde, 20 ml of 0.2 g/1 Na 2 S 2 0 3 - 5H 2 0) until the bands appears clear. -The gel is washed two times for 2 min in water -The reaction is stopped by soaking the gel in 50% ethanol, 12 % acetic acid for 10 min. -The gel is washed for 20 min or longer in 50% ethanol -Soaked in 3 % glycerol, 1 % acetic acid for 2 hours or longer. The gel is then photographed or dried in a gel dryer for longer storage. Example 10: Expression of Xylanase A under the control of the xlnB promoter A 400 bp PCR fragment containing the xylanase B promoter is inserted in front of the xylanase A structural gene and terminator. The construct is used to transform A. tubingensis strain 6M 179, which overproduces xylanase. The hygromycin gene is used as the selection marker in a cotransformation experiment, as in example 2. A total of 232 transformants are screened by a plate assay using 0.25 % congo red. Transformants having a large halo diameter are grown in small scale liquid cultures and the xylanase activity in the culture filtrate is measured. The best transformant (Tl 12-1-27) showed a 1.8x increase in xylanase level compared to the untransformed 6M 179 after a 48 hours induction. Growth/induction experiments to obtain high level of Xylanase A expression The best transformant (T 112-1-27) is grown in large scale fermentation as follows: Spores from the transformant and the control 6M 179 are grown for 7 days in 1 litre of medium containing 25g fibrex 610, 25g wheat bran and 1.4 grams of ammonium sulphate. The cultures are grown in duplicate at two different temperatures (34 °C and 37°C) at 200 rpm and an initial pH of 3.57. Samples of the culture filtrate are collected at days 4, 5, 6 and 7. The samples from day 6 are subjected to anion exchange chromatography using Mono Q and a distinct xylanase A peak is observed. The chromatograph shows a 30% increase in the Xylanase A peak for the transformant containing the xylanase B promoter- xylanase A construct when compared to 6M179. The samples are analysed for xylanase activity expressed as GPU/ml and the results are summarised in the table 3 below and Figure 10. The results demonstrate increased xylanase A production of around 40% . Table 3 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Danisco A/S (B) STREET: Langebrogade 1 . P.O. Box 17 (C) CITY: Copenhagen (E) COUNTRY: Denmark (F) POSTAL CODE (ZIP) : DK-1001 (ii) TITLE OF INVENTION: Expression Element (iii) NUMBER OF SEQUENCES: 15 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO) (2) INFORMATION FOR SEQ ID NO : 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2055 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI- SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Aspergillus tubingensis (ix) FEATURE: (A) NAME/KEY: exon (B) LOCATION: 721..998 (ix) FEATURE: (A) NAME/KEY: intron (B) LOCATION: 999..1062 (ix) FEATURE: (A) NAME/KEY: exon (B) LOCATION: 1063..1462 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: join (721..998, 1063..1462) (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1: AATTGGAGCT CGACTTTACG TACGATGATA AGTAGTGATA GTATGATCCT CAAATTTAAC 60 GCGGCGGTGG CACTCTGCTA AGTCACTAAC GGCAGGAGAT ACACCCCTAA GTTAGCACAC 120 GCTAGCATTT TCCTTCCTAA CTAGATACAG GCAGTATATC TCCGTCTAGA TTCCAGTAGG 180 ATTATAATCA TTGCTAAAGT AGTATACAGT GTCCTAAATG GTTTCATATG CCATCCATGA 240 TTGGATGAGA GTCAACCAAT GGGTCTTACG TAATGAACAA TAAAGCATTG AGCCAGGATG 300 CATTCAACAC AGCAATAGAG TCAGGCTACG CAGGCGGATA TCGATGTTGA CATCAGCGAA 360 TCTAGACCCT TGAAGCTCCA CTGCCTATTG TGAACAGGCG TTATAATTTC AGGATGTCTG 420 CAGGACCTAG AAGGCGATTT AGGCTGTTTC GGGAGATCAA TTCGGCTTTC CAAATCGCCC 480 ACGGATGCTC CACCGACTAG GCTAAACCCC ATCACAGCGA CGTTTCAGGT ACGGCAGGGT 540 CTCACATTTA GGGCCTCGGC AGGGTCTCGG CAGGGTCTCG GCAGGTACCC TTCTTAATAA 600 AGGCTAAATA GCTTCTGCAG AATCATGGGT ATATCAGGAA CGTCTCCTCC GTCGCTGCAG 660 ACCTTCTCTT CTTACTCCGA GCCCCATTGA ATCAACTCCT CAAGCCAAGT CTCTTTCAAC 720 ATG CTT ACC AAG AAC CTT CTC CTC TGC TTC GCC GCA GCT AAG GCT GTT 768 Met Leu Thr Lys Asn Leu Leu Leu Cys Phe Ala Ala Ala Lys Ala Val 1 5 10 15 CTG GCC GTT CCC CAC GAC TCT GTC GTC GAG CGT TCG GAT GCC TTG CAC 816 Leu Ala Val Pro His Asp Ser Val Val Glu Arg Ser Asp Ala Leu His 20 25 30 AAG CTC TCT GAG CGT TCG ACC CCG AGC TCG ACC GGC GAG AAC AAC GGT 864 Lys Leu Ser Glu Arg Ser Thr Pro Ser Ser Thr Gly Glu Asn Asn Gly 35 40 45 TAT TAC TAC TCC TTC TGG ACC GAC GGC GGT GGT GAT GTG ACC TAC ACC 912 Tyr Tyr Tyr Ser Phe Trp Thr Asp Gly Gly Gly Asp Val Thr Tyr Thr 50 55 60 AAC GGT AAC GCT GGC TCG TAC TCC GTC GAG TGG TCC AAC GTT GGC AAC 960 Asn Gly Asn Ala Gly Ser Tyr Ser Val Glu Trp Ser Asn Val Gly Asn 65 70 75 80 TTT GTT GGT GGA AAG GGC TGG AAC GCT GGA AGT GCG AA GTAAGTTAAC 1008 Phe Val Gly Gly Lys Gly Trp Asn Ala Gly Ser Ala Lys 85 90 CTCTCTCAAC CTGTCCCTCT AGGTATTCAG TGAAAAATGC TCACATAACT TCAG G 1063 GAC ATC ACC TAT AGC GGC ACC TTC ACC CCT AGC GGC AAC GGC TAC CTC 1111 Asp lie Thr Tyr Ser Gly Thr Phe Thr Pro Ser Gly Asn Gly Tyr Leu 95 100 105 TCC GTC TAT GGC TGG ACC ACT GAC CCC CTG ATC GAG TAC TAC ATC GTC 1159 Ser Val Tyr Gly Trp Thr Thr Asp Pro Leu lie Glu Tyr Tyr lie Val 110 115 120 125 GAG TCC TAC GGC GAC TAC AAC CCC GGC AGT GGA GGC ACC TAC AAG GGC 1207 Glu Ser Tyr Gly Asp Tyr Asn Pro Gly Ser Gly Gly Thr Tyr Lys Gly 130 135 140 ACC TGC ACC TCC GAT GGA TCT GTC TAC GAT ATC TAC ACG GCT ACC CGT 1255 Thr Cys Thr Ser Asp Gly Ser Val Tyr Asp lie Tyr Thr Ala Thr Arg 145 150 155 ACC AAC GCC CCT TCT ATC CAA GGA ACC GCT ACC TTC ACC CAG TAC TGG 1303 Thr Asn Ala Pro Ser lie Gin Gly Thr Ala Thr Phe Thr Gin Tyr Trp 160 165 170 GTC CGA TTC GAC CAG AAC AAG AGA GTC GGA GGA ACT GTT ACC ACT TCC 1351 Val Arg Phe Asp Gin Asn Lys Arg Val Gly Gly Thr Val Thr Thr Ser 175 180 185 AAC CAC TTC AAC GCT TGG GCT AAG CTG GGC ATG AAC CTG GGT ACT CAC 1399 Asn His Phe Asn Ala Trp Ala Lys Leu Gly Met Asn Leu Gly Thr His 190 195 200 205 AAC TAC CAG ATC CTG GCT ACC GAG GGC TAC CAG AGC AGC GGA TCT TCC 1447 Asn Tyr Gin lie Leu Ala Thr Glu Gly Tyr Gin Ser Ser Gly Ser Ser 210 215 220 TCC ATC ACT ATT CAG TGAGCTTGGA TGTCCAACCG TGCTTGCAGA GATTGCCTGG 1502 Ser lie Thr lie Gin 225 ATGTGGGTGT GGGAAATGAG TGCGATGGTG CTTGCAATAT TGAGCAGTCG TATGATGTGT 1562 GAAACAATTA GTTGCTCGCT ATCAATGCAC TTGTCATTTG AAGTCCATCA AGCGGTCTAG 1622 CGTCGTATTC TTCTTATCTC GAAAAAGTAC ATTACAAAGT ATGTCGGCAG ATCGAGGCGC 1682 GCCACTATCC GAAAGATAAC CTTTTTTTGG TCTAGTTGTA GCAGTTCTGA GACATTAACG 1742 TCAAGTATTA TGCGTGCAAG CTCCCGTCAT ATTGTAGCGG TCATTTCGGA GTAGACGACA 1802 CCGGTTGATC GAGCCATAAC TATGTGAGCT ATAATTTGAA CAGCAGGAGT CCAGACGGTC 1862 CCGACCTCAG TGATTCCAGT AGGCATCTTC TTTTACACGA CAAAAAAGTG TCTCAATCTC 1922 AGACAACCAG CAATTTCACG TTCGGGATGT CCCAACTTAT CTCTTATGAT CCTGCAACAC 1982 GTCTACCAAT GAAAGCCACT TTTTACTATG TAAGTAAAAA TCGACAAGCC CGTCAGCGCC 2042 CATGGACAAG CTT 2055 (2) INFORMATION FOR SEQ ID NO : 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 226 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Leu Thr Lys Asn Leu Leu Leu Cys Phe Ala Ala Ala Lys Ala Val 1 5 10 15 Leu Ala Val Pro His Asp Ser Val Val Glu Arg Ser Asp Ala Leu His 20 25 30 Lys Leu Ser Glu Arg Ser Thr Pro Ser Ser Thr Gly Glu Asn Asn Gly 35 40 45 Tyr Tyr Tyr Ser Phe Trp Thr Asp Gly Gly Gly Asp Val Thr Tyr Thr 50 55 60 Asn Gly Asn Ala Gly Ser Tyr Ser Val Glu Trp Ser Asn Val Gly Asn 65 70 75 80 Phe Val Gly Gly Lys Gly Trp Asn Ala Gly Ser Ala Lys Asp lie Thr 85 90 95 Tyr Ser Gly Thr Phe Thr Pro Ser Gly Asn Gly Tyr Leu Ser Val Tyr 100 105 110 Gly Trp Thr Thr Asp Pro Leu lie Glu Tyr Tyr lie Val Glu Ser Tyr 115 120 125 Gly Asp Tyr Asn Pro Gly Ser Gly Gly Thr Tyr Lys Gly Thr Cys Thr 130 135 140 Ser Asp Gly Ser Val Tyr Asp lie Tyr Thr Ala Thr Arg Thr Asn Ala 145 150 155 160 Pro Ser lie Gin Gly Thr Ala Thr Phe Thr Gin Tyr Trp Val Arg Phe 165 170 175 Asp Gin Asn Lys Arg Val Gly Gly Thr Val Thr Thr Ser Asn His Phe 180 185 190 Asn Ala Trp Ala Lys Leu Gly Met Asn Leu Gly Thr His Asn Tyr Gin 195 200 205 lie Leu Ala Thr Glu Gly Tyr Gin Ser Ser Gly Ser Ser Ser lie Thr 210 215 220 He Gin 225 (2) INFORMATION FOR SEQ ID NO : 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 907 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI- SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: CACTATTGGC GCCCCACCCA GTGGAGACTT ATACTACAAG GTATCGGGCG GCTATCTGAG 60 CAATCGGATC TTCTTAAGCC ACAGGCTAAT ATCAAAACAC TTGTGGCGTC TAGCCTTGTT 120 TTTATTTGAC CGTCGGGAAG CCGGTTCTGC ACAACCTTTT CCCTCGCGTT CTACTTTCCA 180 ATTAGGTTTC ATGCGAAGGA TCTCAATTGG CACCTTCCTT AATAAGTAGT GATAGTATTA 240 TCCTCAAATT TAACGCGGCG GTGGCACTCT GCTAAGTCAC TAACGGCAGG AGACACTCCC 300 TCAAGTTAGC ACACGCTAGC ATTTTCTTTC TTAACTAGGT AGAAGCAGTA CGTCTCCGTC 360 TAGATTCCAG TAGAATTATA ATCATTGTTA AAGTAGTATA CAGTGTCATA AATGGTTTTA 420 CATGCCATCC ATGATTGGAT GAGAGCCAAC CAATGGGTCT TACGTAATGG ACAATGAAGC 480 ATTCGAGCCA GGATGCATTT AACGCAGCAA GAGTCAGGCT ACACAGGTGG ATATCGATGT 540 TCACAACCGT AAATCTAGAC CCTTGAAGCT CCACTGCCTA TTCGAACAGG CATTATGATT 600 TCAGGATGTC TGCAGGACCC TAGAAGGCGA TTTAGGCTGT TTCGGAGATC AATTCGGCTT 660 CCAAATCGCC CACGGATGCT CCACCGACTA GGCTAAACCC CATCACAGCG GACGTTTCAG 720 GTACGGCAGG GTCTCACATT TAGGGCCTCG GCAGGGTCTC GGCAGGTACC CTTCTTAATA 780 AAGGCTAAAT AGCTTCTGCA GAATCATGGG TATATCAGGA ACGTCTCCTC CGTCGCTGCA 840 GACCTTCTCT TCTTACTCCC AGTCCCATTG AATCAACTCC TCAAGCCAAG TCTCTTTCAA 900 CATGATG 907 ( 2 ) INFORMATION FOR SEQ ID NO : 4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2967 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: GAATTCATCC CGGTCGGTGT CCAGTCCCAG GCGGTGAACT TACAGTAGCA AGCTGTAAAC 60 TTACCTCAGG TACACTGTCA GAAGCAGATA ATCTCATTAT TGATGAGACT TTCACGCTCT 120 CCTGAGCCAT AAAAGGAGTA CCTTTTTTTT GAAGAACAGC TCCACATCTT AGTTACTGAT 180 ACCTCATCAC AAGTCGCCAG GAAATGCCAG TAACGTCTGC AGGCCTGTAC TATTTACCAA 240 GAAGGCCAGG TCACTGGTGG ATATACAACT TTGTTATAGG TTGCGGGAGT CAGCCCCTAC 300 TCCCTGATGG GTTCCCACTC CCCAGTCATT TCCTACTGGA TAGTAGGCTC CTAGAGTTGG 360 GTAAAGATTG CCAAGGGTTT AGGCCCAATC TTGTATATGC TTGGCTAGGC AGGACCTCGG 420 TAAACTGATG GCTCCTGCAT TTTGACCTGA GTATTTCCAG CTATAAGCGA GATTTGCAAT 480 ACTCTGCCTT CATCACCTAC AGAAAGAACT CCTCGGCCAA CTCCCGGTGG CCTTTGAGCT 540 CCAAAGTACC TTCGATCAAG CTTCGCGATC TTTTGGCCAG TGTTTCTCGC AGCGTTAACT 600 GAGCCTAAGG CTTGCATCAA GAAATAAAGA AACATAACCC TGCACTACAT ACGTCTTGTA 660 TGAGCGATGA ACTGTGTTCA TTCAGTAGAT CAGTGGGTAC ATAATCATGA ACATACTTTT 720 AGTAAGAAAA CCTTCTGCAG GACGCCGGTC AAGAATCCCC ACTTCCCCGC CTCCCCCAAC 780 TCGCAGCCCT TTTATCCGTC TGCCGTCCAT TTAGCCAAAT GTAGTCCATT TAGCCAAGTG 840 CGGTCCATTT AGCCAAGACC AGTGGCTAGA TTGATAGCTA GCACAGGAAA CGCATGACTG 900 AGACACAACT ATAGAACTGT CTCTGGAAAT AGGCTCGAGG TTGTTCAAGC GTTTAAGGTG 960 ATGCGGCAAA ATGCATATGA CTGAGCTGCT TCATCTTGCA GGGGGAAGGG ATAAATAGTC 1020 TTTTTCGCAG AATATAAATA CAGGGAGAGT GGGCTCGCAG CAATATTGAC CAGCACAGCG 1080 CTGCTCTCCA GTTGCATAAA TACCATCACC AGGATTTAGC TTCTTCAATC ATCATGAAGG 1140 TCACTGCGGC TTTTGCAGGT CTTTTGGTCA CGGCATTCGC CGCTCCTGTG CCGGAACCTG 1200 TTCTGGTGTC GCGAAGTGCT GGTATTAACT ACGTGCAAAA CTACAACGGC AACCTTGGTG 1260 ATTTCACCTA TGACGAGAGT GCCGGAACAT TTTCCATGTA CTGGGAAGAT GGAGTGAGCT 1320 CCGACTTTGT CGTTGGTCTG GGCTGGACCA CTGGTTCTTC TAAGTGAGTG ACTGCATTCT 1380 TTAACCAAAG TCTAGGATCT AACGTTTTTT AGCGCTATCA CCTACTCTGC CGAATACAGT 1440 GCTTCTGGCT CCTCTTCCTA CCTCGCTGTG TACGGCTGGG TCAACTATCC TCAGGCTGAA 1500 TACTACATCG TCGAGGATTA CGGTGATTAC AACCCTTGCA GCTCGGCCAC AAGCCTTGGT 1560 ACCGTGTACT CTGATGGAAG CACCTACCAA GTCTGCACCG ACACTCGAAC AAACGAACCG 1620 TCCATCACGG GAACAAGCAC GTTCACGCAG TACTTCTCCG TTCGGGAGAG CACGCGCACA 1680 TCTGGAACGG TGACTGTTGC CAACCATTTC GACTTCTGGG CGCAGCATGG GTTCGGCAAT 1740 AGCGACTTCA ATTATCAGGT CATGGCAGTG GAAGCATGGA GCGGTGCTGG CAGCGCCAGT 1800 GTCACGATCT CCTCTTAGGA GATAGTGCCT TAGTAGTCGG AAGATGTCAA CGCGAGCTTT 1860 GTTCTCAGCT GGTGTGATGA TCGGATCCGG TTCTCTAGCG GTTACATTGA GGCTGTATAA 1920 GCTGTTGTGG GGCCGAGCTG TCAGCGCTGC GTTTTCAACT TGCACAGATA ATCAACTCTC 1980 GTTTACTATT TCTTGCGTTT TCTCGCTGCT TATCCTATCC ATAGATAATA TTTTGCTCAA 2040 TACATATTAT CTATATACAA CTTTTTCAGT CGCAGTAGTC ACTCCGAGCA AGGCATTGGG 2100 AAATCGGGGG ATGCGGGGTG CTGCGTAGCC TCTAACCTAG GGCATTTAAA GGATATTTAA 2160 TCTCCGGATA TCCTATACTA ACAGACTCCT AATGACTGCG GAAAATATAG AGGGCCAGGA 2220 TCTCTACAAT TCGACGAAGT TCAATGCAAT CAGAGGGGGA ATAACTAATG AGAGTGCAAT 2280 GAGTTAGAGA AGGACAATAT GGCAGTCTTA GTGTGGACTT ACATAACGAT ATGGAGTATA 2340 GAAAAAAGTG GGGAGGTCCG TCTACTATAT ATAATGCCCA TTACGTGTAT CCGATGCTTG 2400 CCCATTGCCA CTGAGTAGGT GACTCTTCGA GTCCACTTAA CATCGGTATA TGAGAAAATC 2460 ATGCCCCCTT TGCAGGAAAC TTAGCTTTTC ATTCCTTGTT TGAAGCCATA ATTATCACGA 2520 AACCCATTAA AGACTTATCT TCCTGTAACT GAAACAAATA TTTCGGGATT GGAATAGCCT 2580 TTTGCCCGAC ATCAGTATTT TTTTGCGACG GTAAATCTGG GAGTATACGA TGTCCTTTCA 2640 CGCATCTCAA CAAAACTCTG TCGCATCGGG TAACCTACGG ATAGTACTGT ATCCAGACGC 2700 ATTTTTTCTA ATAACAGGTC ACTGTGCAAT TTCCGGGAAA GTTTCTATGT ATAATACTCT 2760 CTCGTTGCAT CTCAAATATT GTGGCTGATT GAGACCCACA CTATGTCTTG CATCTATTGT 2820 ACCATCCTTG CTTGAGGCCA ATTGGCGCAC CTGTACCCGG TTAATGATAT AATGATGAAG 2880 CTGCAGCTGG TTACCAATGG GAATGACATA CCATGTACAT AAACTGCCAG CGTCACAGAG 2940 GAGCTGTCAA TAGTACTGAA ATCTAGA 2967 (2) INFORMATION FOR SEQ ID NO : 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3311 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: GTTCAATTGG GCGTGATGAG ATGCCGTCGC GGGTGGAGTT GTCTGCCCAT CACAATAAAC 60 CTTTGTCCAA ACATTTGCCT AATTGCCCAT CACCAACGGC TTTAAGAATC ATGTACCTCG 120 CTCATTTGAG AAGATGGAAG ATGCCATTGC CACGGCAGTC GATCAATCTA CTGGCTATGG 180 ATGGTCCGAA TTTTCCGTCG TCGCCTTTTG CTCTAATCTC GGTATGACCT TCACCGAGCG 240 AATCGTAGAA TATTTAAAGG GTTGATCGAG CCACTTTGTC GCCGATGTCT GACTCTGTCG 300 TGTCACAACT GAACTGATCA GACGAGGTCA TCTGAGTCTC TCGTCGAAAA AAGACTCGTT 360 GGATGATTCT CGATTTCAAC TCGGGACAAG TCATAGAACG AGTAGTACTT CAGTTGGCCA 420 CAAAAGATGA AGTCTCTCGC CGCAATTGCT GCTCTGCTGT CGCCCACACT GGTCCGGGCA 480 GCGACTCCGG ATGAGTGGAA AGCTCAGTCG ATCTATTTCA TGCTGACGGA CCGGTTTGCG 540 CGTACCGACA ATTCGACCAC GGCTCCCTGT GACACCACTG CCGGGGTATG CAACTAACCC 600 TGTGTTTCTC TTCCCGGGAC GTACAAGGGG TCTTCTCCAT GCTAACCGTG CACATGCAGA 660 AATATTGCGG GGGAACATGG CGAGGTATCA TCAACAACGT AAGTGGCTTC TGATTTTCGC 720 TCAATAATCT TCGTCGCGTG ACTTTATTTC CTAGCTGGAT TACATCCAGG ATATGGGCTT 780 CACAGCTATC TGGATAACTC CAGTGACAGC CCAGTGGGAC GACGATGTGG ATGCGGCAGA 840 TGCAACGTCG TATCACGGTT ATTGGCAGAA AGACCTGTGC GCAACCCTGC TCCATGGATC 900 GCTGGCTGCA AACTCGTGCT GATCGGTGAT TTTTTTTTTT TTTTTTTTGA AACAGATACT 960 CTCTGAATTC GAAATTCGGC ACTGCCGATG ACTTGAAAGC CCTGGCTGAT GCCCTTCACG 1020 CCCGTGGGAT GCTTCTCATG GTCGACGTCG TGGCTAATCA CTTTGTACGG ACCATCTACA 1080 TACCTGGGAA ACGCGAAGAA GGAAAAAAAA AAAAAGGCGC ACGCTAACAT TTCGCGTTTA 1140 GGGCTACGGC GGTTCTCATA GCGAGGTGGA TTACTCGATC TTCAATCCTC TGAACAGCCA 1200 GGATTACTTC CACCCGTTCT GTCTCATTGA GGACTACGAC AACCAGGAAG AAGTCGAACA 1260 ATGCTGGCTG GCCGATACTC CGACGACATT GCCCGACGTG GACACCACCA ATCCTCAGGT 1320 TCGGACGTTT TTCAACGACT GGATCAAGAG CCTGGTGGCG AACTACTCCA GTATGATTGT 1380 TCCCGCGGTA ACGCTTTAGG GCTTGCTCTA ACTGAAATCG ACAGTCGATG GTCTGCGCGT 1440 CGACACCGTT AAGCACGTGG AGAAAGATTT CTGGCCCGAC TTCAACGAAG CTGCTGCGTG 1500 TACCGTCGGC GAGGTGTTCA ACGGTGACCC AGCGTACACC TGCCCATACC AGGAAGTGCT 1560 GGATGGCGTT CTGAACTATC CGATGTGAGT GATTCCGAAA GTTCCATCGA TCAGGCTTTC 1620 TGACGCATGA GAACAGCTAC TATCCTGCGC TTGATGCATT CAAGTCTGTC GGCGGCAATC 1680 TCGGCGGCTT GGCTCAGGCC ATCACCACCG TGCAGGAGAG CTGCAAGGAT TCCAATCTGC 1740 TCGGCAATTT CCTTGAGAAT CACGACATTG CTCGCTTTGC TTCGTATGGA CACTCTTTTT 1800 GAAGCCCTCA TCGATTGGGG ATGCTGACAC GGACAACAAC AACAGGTACA CGGATGACCT 1860 TGCTCTCGCC AAGAATGGTC TCGCTTTCAT CATCCTCTCG GATGGTATTC CGATCATCTA 1920 CACGGGCCAG GAGCAGCACT ACGCCGGTGA TCACGATCCC ACAAATCGTG AGGCCGTCTG 1980 GCTGTCTGGC TACAATACCG ACGCCGAGCT GTACCAGTTC ATCAAGAAGG CCAATGGCAT 2040 CCGCAACTTG GCTATCAGCC AGAACCCGGA ATTCACCTCC TCCAAGGTGA GTACAATAAC 2100 AAACTTTTCG AAAAATTTTT CACCGGAGAA AACCTAAGAT TCGGCTAACA AAACAAAAAA 2160 AAAAAAGACC AAGGTCATCT ACCAAGACGA TTCGACCCTT GCCATTAACC GGGGCGGCGT 2220 CGTTACTGTC CTGAGCAATG AAGGCGCCTC CGGGGAGACC GGGACTGTCT CCATTCCGGG 2280 AACTGGCTTC GAGGCCGGCA CGGAATTGAC TGATGTCATC TCCTGCAAGA CCGTGACTGC 2340 GGGGGACAGC GGGGCGGTCG ACGTGCCCTT GTCGGGCGGA CTGCCAAGCG TGCTCTATCC 2400 CAGCTCCCAG CTGGCCAAGA GTGGTCTGTG TGCGTCGGCG TGAGGGGATT CTCTCATCAC 2460 CAGGCGATGT CAGGAGACAA TTTTTTTCTG AACTCAGGGG TTTCTCAGAG AGCTCAAAAT 2520 CGGGAACTTT TTTTTTGCAG GAACTCCGAG TGTACATATA TTGAGTGGAG TCTCTCATTC 2580 GTCTTTTGTG TAGCTTAGGT TGATCCATAG TGAGTGATTT TTCACGTTGC TCCACGTGGT 2640 TTTCTTGACA ' GTTCGGGCTA TGGGGTGTTA GCCTTGTTGG GCACGAAGAT CCACACTAAA 2700 ATCTGACACT ATGAAGTCAA CTCACCATCC TGATCGGATT TGTGCTCTCA TTCCGTCATT 2760 TGTCCAATCA ACTCTCCGTA AACCCCCATC CTAACTCCCT CCCCAAGTGA ACCTATTCCC 2820 TTTCTTGTTT CGTAAGCTCC CCAAGGTCCA ATGGCCATGT CACTTTGATG ACGCGTAGCA 2880 CGTCAGCTGT TCCGTACCTT TTCTCGCCCG ATCAGCGGCG GCGGCGGCGG CGGCGGCGGC 2940 AGCAGCAGCA GCAGCAGCAG CAGCAGCAGC AGCAGTCAAG GGGACCAAAC CAGGAACCCA 3000 ATTCGGCAGG GAGACGCGCC GAATCCGCCG ACGTTGAACG CGGCTAGGAG ATTCTTCGCA 3060 CTTTGTCCCT TTCCCATTGC TCCTCGTCAT TGTAGCTTAT TCCTAGTCTC GTTAAACCCG 3120 GAACTAGCGG CCGAATGATT TGGCCACCGC TTCCATACTA TGGTACACCT GCGCTGTACT 3180 CCGGACGCAG AATGTCGGCC TTTACGCCCC AATCCCTGTA CCTCGGAGTT ATGGTTCGAA 3240 GAGTGAATCC TCTTCGATTG CACACTTCAT GACACAGAAG CCGCTTCGTA ATCCCAATCC 3300 AATTGCTGCA G 3311 (2) INFORMATION FOR SEQ ID NO : 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7432 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: GATCCACTAG TTCTAGAGCG GCCGCCACCG CGGTGGAGCT CCAGCTTTTG TTCCCTTTAG 60 TGAGGGTTAA TTGCGCGCTT GGCGTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT 120 TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA TAAAGTGTAA AGCCTGGGGT 180 GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT CACTGCCCGC TTTCCAGTCG 240 GGAAACCTGT CGTGCCAGCT GCATTAATGA ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG 300 CGTATTGGGC GCTCTTCCGC TTCCTCGCTC ACTGACTCGC TGCGCTCGGT CGTTCGGCTG 360 CGGCGAGCGG TATCAGCTCA CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT 420 AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC 480 GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC 540 TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA 600 AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT 660 CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG 720 TAGGTCGTTC GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC 780 GCCTTATCCG GTAACTATCG TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG 840 GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC 900 TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG 960 CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC 1020 GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT 1080 CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACTCACGT 1140 TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA 1200 AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA 1260 TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC 1320 TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT 1380 GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA 1440 GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT 1500 AATTGTTGCC GGGAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT 1560 GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC 1620 GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC 1680 TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG CAGTGTTATC ACTCATGGTT 1740 ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT 1800 GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC GGCGACCGAG TTGCTCTTGC 1860 CCGGCGTCAA TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT 1920 GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG 1980 ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT 2040 GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAAGG GAATAAGGGC GACACGGAAA 2100 TGTTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT 2160 CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC 2220 ACATTTCCCC GAAAAGTGCC ACCTAAATTG TAAGCGTTAA TATTTTGTTA AAATTCGCGT 2280 TAAATTTTTG TTAAATCAGC TCATTTTTTA ACCAATAGGC CGAAATCGGC AAAATCCCTT 2340 ATAAATCAAA AGAATAGACC GAGATAGGGT TGAGTGTTGT TCCAGTTTGG AACAAGAGTC 2400 CACTATTAAA GAACGTGGAC TCCAACGTCA AAGGGCGAAA AACCGTCTAT CAGGGCGATG 2460 GCCCACTACG TGAACCATCA CCCTAATCAA GTTTTTTGGG GTCGAGGTGC CGTAAAGCAC 2520 TAAATCGGAA CCCTAAAGGG AGCCCCCGAT TTAGAGCTTG ACGGGGAAAG CCGGCGAACG 2580 TGGCGAGAAA GGAAGGGAAG AAAGCGAAAG GAGCGGGCGC TAGGGCGCTG GCAAGTGTAG 2640 CGGTCACGCT GCGCGTAACC ACCACACCCG CCGCGCTTAA TGCGCCGCTA CAGGGCGCGT 2700 CCCATTCGCC ATTCAGGCTG CGCAACTGTT GGGAAGGGCG ATCGGTGCGG GCCTCTTCGC 2760 TATTACGCCA GCTGGCGAAA GGGGGATGTG CTGCAAGGCG ATTAAGTTGG GTAACGCCAG 2820 GGTTTTCCCA GTCACGACGT TGTAAAACGA CGGCCAGTGA GCGCGCGTAA TACGACTCAC 2880 TATAGGGCGA ATTGGCGGGC CCGTCTCTCA TCCATGGTTC CTCTTCGGCC TCGACCATCC 2940 CATCACTGCC ATACCTGCAC TCGTTGTTTT CTCTTGCATT CACATCGCGG TGTTCATCCA 3000 CGAACATCAT CTATCCGATA AGGCTGATGA GGAGAACTAT GTATATCCTA TGACCAGTGG 3060 GTCGTCAGAT CCCTACTTCA TACGCAATTC GTTGAGCTAT ACTCGATGAT CGTTGATAAG 3120 AATCCACTGA CTACTTATTA CGGTGTACAA CGTGCACTAT TTCAGCGACA GGCGTGCCTC 3180 ACTGCCTAGT GCCTACAGGT AACACTCAAC AGAATGCACA AGGATGGAGC GTCCAAAACG 3240 GAATGCCTTG TGACGTCAGT CAGTGCGCTG CCACTAATGT ATACTAGTAC TCCTCTCTGT 3300 ACCACCACCG CCCACCCGGA CAAGATACTC CGTATAGTTC TCCGATGCAC CGCATCTTGC 3360 GACCCACCCA GACCTCAAAG ATATGCCTCC AGGATGACGG TATCGCTCTC TGAGAAACCC 3420 CTGAGTTCAG AAAAAAATTG TCTCCTGACA TCGCCTGGTG ATGAGAGAAT CCCCTCACGC 3480 CGACGCACAC AGACCACTCT TGGCCAGCTG GGAGCTGGGA TAGAGCACGC TTGGCAGTCC 3540 GCCCGACAAG GGCACGTCGA CCGCCCCGCT GTCCCCCGCA GTCACGGTCT TGCAGGAGAT 3600 GACATCAGTC AATTCCGTGC CGGCCTCGAA GCCAGTTCCC GGAATGGAGA CAGTCCCGGT 3660 CTCCCCGGAG GCGCCTTCAT TGCTCAGGAC AGTAACGACG CCGCCCCGGT TAATGGCAAG 3720 GGTCGAATCG TCTTGGTAGA TGACCTTGGT CTTTTTTTTT TTTGTTTTGT TAGCCGAATC 3780 TTAGGTTTTC TCCGGTGAAA AATTTTTCGA AAAGTTTGTT ATTGTACTCA CCTTGGAGGA 3840 GGTGAATTCC GGGTTCTGGC TGATAGCCAA GTTGCGGATG CCATTGGCCT TCTTGATGAA 3900 CTGGTACAGC TCGGCGTCGG TATTGTAGCC AGACAGCCAG ACGGCCTCAC GATTTGTGGG 3960 ATCGTGATCA CCGGCGTAGT GCTGCTCCTG GCCCGTGTAG ATGATCGGAA TACCATCCGA 4020 GAGGATGATG AAAGCGAGAC CATTCTTGGC GAGAGCAAGG TCATCCGTGT ACCTGTTGTT 4080 GTTGTCCGTG TCAGCATCCC CAATCGATGA GGGCTTCAAA AAGAGTGTCC ATACGAAGCA 4140 AAGCGAGCAA TGTCGTGATT CTCAAGGAAA TTGCCGAGCA GATTGGAATC CTTGCAGCTC 4200 TCCTGCACGG TGGTGATGGC CTGAGCCAAG CCGCCGAGAT TGCCGCCGAC AGACTTGAAT 4260 GCATCAAGCG CAGGATAGTA GCTGTTCTCA TGCGTCAGAA AGCCTGATCG ATGGAACTTT 4320 CGGAATCACT CACATCGGAT AGTTCAGAAC GCCATCCAGC ACTTCCTGGT ATGGGCAGGT 4380 GTACGCTGGG TCACCGTTGA ACACCTCGCC GACGGTACAC GCAGCAGCTT CGTTGAAGTC 4440 GGGCCAGAAA TCTTTCTCCA CGTGCTTAAC GGTGTCGACG CGCAGACCAT CGACTGTCGA 4500 TTTCAGTTAG AGCAAGCCCT AAAGCGTTAC CGCGGGAACA ATCATACTGG AGTAGTTCGC 4560 CACCAGGCTC TTGATCCAGT CGTTGAAAAA CGTCCGAACC TGAGGATTGG TGGTGTCCAC 4620 GTCGGGCAAT GTCGTCGGAG TATCGGCCAG CCAGCATTGT TCGACTTCTT CCTGGTTGTC 4680 GTAGTCCTCA ATGAGACAGA ACGGGTGGAA GTAATCCTGG CTGTTCAGAG GATTGAAGAT 4740 CGAGTAATCC ACCTCGCTAT GAGAACCGCC GTAGCCCTAA ACGCGAAATG TTAGCGTGCG 4800 CCTTTTTTTT TTTTTCCTTC TTCGCGTTTC CCAGGTATGT AGATGGTCCG TACAAAGTGA 4860 TTAGCCACGA CGTCGACCAT GAGAAGCATC CCACGGGCGT GAAGGGCATC AGCCAGGGCT 4920 TTCAAGTCAT CGGCAGTGCC GAATTTCGAA TTCAGAGAGT ATCTGTTTCA AAAAAAAAAA 4980 AAAAAAAATC ACCGATCAGC ACGAGTTTGC AGCCAGCGAT CCATGGAGCA GGGTTGCGCA 5040 CAGGTCTTTC TGCCAATAAC CGTGATACGA CGTTGCATCT GCCGCATCCA CATCGTCGTC 5100 CCACTGGGCT GTCACTGGAG TTATCCAGAT AGCTGTGAAG CCCATATCCT GGATGTAATC 5160 CAGCTAGGAA ATAAAGTCAC GCGACGAAGA TTATTGAGCG AAAATCAGAA GCCACTTACG 5220 TTGTTGATGA TACCTCGCCA TGTTCCCCCG CAATATTTCT GCATGTGCAC GGTTAGCATG 5280 GAGAAGACCC CTTGTACGTC CCGGGAAGAG AAACACAGGG TTAGTTGCAT ACCCCGGCAG 5340 TGGTGTCACA GGGAGCCGTG GTCGAATTGT CGGTACGCGC AAACCGGTCC GTCAGCATGA 5400 AATAGATCGA CTGAGCTTTC CACTCATCCG GAGTCGCTGC CCGGACCAGT GTGGGCGACA 5460 GCAGAGCAGC AATTGCGGCG AGAGACTTCA TCTTTTGTGG CCAACTGAAG TAATTCCTGC 5520 AGCCCTTGAA AGAGACTTGG CTTGAGGAGT TGATTCAATG GGGCTCGGAG TAAGAAGAGA 5580 AGGTCTGCAG CGACGGAGGA GACGTTCCTG ATATACCCAT GATTCTGCAG AAGCTATTTA 5640 GCCTTTATTA AGAAGGGTAC GTACCTGCCG AGACCCTGCC GAGACCCTGC CGAGGCCCTA 5700 AATGTGAGAC CCTGCCGTAC CTGAAACGTC GCTGTGATGG GGTTTAGCCT AGTCGGTGGA 5760 GCATCCGTGG GCGATTTGGA AAGCCGAATT GATCTCCCGA AACAGCCTAA ATCGCCTTCT 5820 AGGTCCTGCA GACATCCTGA AATTATAACG CCTGTTCACA ATAGGCAGTG GAGCTTCAAG 5880 GGTCTAGATT CGCTGATGTC AACATCGGGG GGATCGCAGG GAAAAATACG AGCTCCAATG 5940 AACCTGGGTG TGGCAACTTC AATGGAAAGG AACTGCCTTT GCAGGTGTGG CTGAACCCCA 6000 CGGTTCCGGT CGGAGGCGGC GAAATCACCC GATGTGGCTG GTGCGTGGAG GGTCGCGATG 6060 ATTTACTGAG CTCCTCTTTT GCTCGACATT GAATGTGCAT TGTTCACCTC ATATAAGGGC 6120 CAGTCGCTGC TAAATTATTC GGTAGTATTT GCGCATCTCT GGATCTACCA ATTAGGGCCT 6180 ATCAGTCGAA ACTCCAAGCT ACTCATATTG CACAAGCCTC TTTCATCCCC GCATTAACCC 6240 CTCCACCGAC ACCATGTCCT CCAAGTCGCA ATTGACCTAC ACTGCCCGTG CCAGCAAGCA 6300 CCCCAATGCT CTGGCCAAGC GGCTGTTCGA AATTGCTGAG GCCAAGAAGA CCAATGTGAC 6360 CGTCTCTGCC GACGTTACCA CCACTAAGGA GCTACTAGAT CTTGCTGACC GTAGGCCGAC 6420 CCGCCATTCT GCCTGTTTAT GCTGCATACA AACTTATTAA CGGTGATACC GGACTGAGGT 6480 CTCGGTCCCT ACATCGCCGT GATCAAAACC CACATCGATA TCCTCTCTGA CTTCAGCGAC 6540 GAGACCATTG AGGGCCTCAA GGCTCTTGCG CAGAAGCACA ACTTCCTCAT CTTCGAGGAC 6600 CGCAAATTCA TCGACATTGG CAACACTGTC CAGAAGCAAT ACCACCGTGG TACCCTCCGC 6660 ATCTCAGAAT GGGCCCATAT CATCAACTGC AGCATCCTGC CTGGCGAGGG TATCGTCGAG 6720 GCTCTCGCTC AGACGGCGTC TGCACCGGAC TTCTCCTACG GCCCCGAACG TGGTCTGTTG 6780 ATCTTGGCGG AAATGACCTC TAAGGGTTCC TTGGCCACCG GCCAGTACAC TACTTCTTCG 6840 GTTGATTATG CCCGGAAATA CAAGAACTTC GTCATGGGAT TTGTGTCGAC CCGCTCGTTG 6900 GGTGAGGTGC AGTCGGAAGT CAGCTCTCCT TCGGATGAGG AGGACTTTGT GGTCTTCACG 6960 ACTGGTGTGA ACATTTCGTC CAAGGGAGAT AAGCTCGGTC AGCAGTACCA GACTCCCGCA 7020 TCGGCTATCG GTCGGGGTGC TGACTTCATT ATCGCGGGTC GCGGTATCTA CGCCGCGCCG 7080 GACCCGGTGC AGGCTGCGCA ACAGTACCAG AAGGAAGGTT GGGAGGCGTA CCTGGCCCGT 7140 GTCGGCGGAA ACTAATACTA TAAAATGAGG AAAAAAGTTT TGATGGTTAT GAATGATATA 7200 GAAATGCAAC TTGCCGCTAC GATACGCATA CAAACTAATG TCGAGCACGG GTAGTCAGAC 7260 TGCGGCATCG GATGTCAAAA CGGTATTGAT CCTGCAGGCT ATTATAGGGT GGCACGGGAT 7320 TAATGCGGTA CGACGATTTG ATGCAGATAA GCAGGCTGCG AAGTACTTAG TCCTGTAACT 7380 CTTGCGTAGA GCAAATGGCG ACGGGTGGCT GATAAGGGAC GGTGATAAGC TT 7432 (2) INFORMATION FOR SEQ ID NO : 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic DNA" (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: CGGCAGGGTC TC 12 (2) INFORMATION FOR SEQ ID NO : 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic DNA" (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: GAGACCCTGC CG 12 (2) INFORMATION FOR SEQ ID NO : 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic DNA" (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9: TCGACTGAGC TTTCCACTCA T 21 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 63 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: TACGTACCTG CCGAGACCCT GCCGAGACCC TGCCGAGGCC CTAAATGTGA GACCCTGCCG 60 TAC 63 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: TACGAGACCC TGCCGAGGCC CTAAATGTGA GACCCTGCCG TAC 43 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: TACGAGACCC TGCCGAGACC CTGCCGAGGC CCTAAATGTG AGACCCTGCC GTAC 54 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 75 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: TACGAGACCC TGCCGGTACC TGCCGAGACC CTGCCGAGAC CCTGCCGAGG CCCTAAATGT 60 GAGACCCTGC CGTAC 75 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 87 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: TACGAGACCC TGCCGGAGAC CCTGCCGGTA CCTGCCGAGA CCCTGCCGAG ACCCTGCCGA 60 GGCCCTAAAT GTGAGACCCT GCCGTAC 87 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 99 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: TACGAGACCC TGCCGCGGCA GGGTCTCCGG CAGGGTCTCG TACCTGCCGA GACCCTGCCG 60 AGACCCTGCC GAGGCCCTAA ATGTGAGACC CTGCCGTAC 99

Claims: Claims. 1. The use of a nucleic acid element having the sequence CGGCAGGGTCTC to modulate transcription of a nucleotide sequence from a promoter. 2. Use according to claim 1, wherein a total of three elements having the sequence CGGCAGGGTCTC are used to upregulate transcription of a nucleotide sequence from a promoter. 3. A nucleic acid construct comprising a promoter which is operatively linked to a nucleotide sequence, characterised in mat at least one heterologous copy of the element CGGCAGGGTCTC has been operatively linked to the promoter. 4. A construct according to claim 3 which is an expression vector. 5. A construct according to claim 3 or claim 4 which comprises more than one copy of the element CGGCAGGGTCTC. 6. A construct according to claim 5, which contains 3 copies of the element CGGCAGGGTCTC. 7. A construct according to claim 5 which comprises 4 or more copies of the element CGGCAGGGTCTC. 8. Use according to claim 1, or a construct according to any one of claims 3 to 7, wherein the element is placed upstream of the promoter which is operatively linked to the nucleotide sequence. 9. Use according to claim 1, or a construct according to any one of claims 3 to 7, wherein the promoter is a fungal promoter. 10. Use according to claim 1, or a construct according to any one of claims 3 to 7, wherein the nucleotide sequence is a heterologous nucleotide sequence. 11. A host cell transformed with a construct according to any one of claims 3 to 10. 12. A host cell according to claim 11 which is a plant cell or a fungal cell. 13. A transgenic organism transformed with a construct according to any one of claims 3 to 10. 14. A transgenic organism according to claim 13 which is a fungus. 15. A sequence variant of the A. tubingensis xlnB promoter which possesses at least three copies of the element CGGCAGGGTCTC. 16. A sequence variant of the A. tubingensis xlnB promoter according to claim 14 which has the sequence set forth in SEQ. ID. No. 3. 17. A method for modulating the level of transcription of a nucleotide sequence from a promoter, comprising the steps of inserting at least one exogenous copy of the element CGGCAGGGTCTC such that it is operably linked to the promoter, and causing the nucleotide sequence to be transcribed from the promoter. 18. A nucleic acid construct according to any one of claims 3 to 10, comprising a sequence obtainable from pXylA, deposited at die NCIMB under accession No. 40861, pXylB, deposited at the NCIMB under accession No. 40862, or p /nB-AmyA, deposited at the NCIMB under accession No. 40858.

Inventors: RASMUSSEN PREBEN, RASMUSSEN, PREBEN
Applicants: DANISCO, RASMUSSEN PREBEN, DANISCO A/S, RASMUSSEN, PREBEN
Application year: 1998
Main classification: C12N15
IPC codes: C12N1, C12N9, C12N15